ChapterPDF Available
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us?
Numbers displayed above are based on latest data collected.
For more information visit
Open access books available
Countries delivered to Contributors from top 500 universities
International authors and editor s
Our authors are among the
most cited scientists
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
TOP 1%
Melatonin for a Healthy Heart
Natalia JorgelinaPrado, MargaritaSegovia-Roldan,
EmilianoRaúlDiez and EstherPueyo
Melatonin is a promising cardioprotective agent. Its increase during the night
is associated with healthy cardiovascular function. On the other hand, reduced
levels of melatonin are related to diseases. Aging and chronodisruptors reduce
melatonin levels. Pharmacological supplementation reduces the deleterious effects
of cardiovascular risk factors and improves the myocardial response to ischemia/
reperfusion injury and other proarrhythmic conditions. The protective mecha-
nisms of melatonin involve its antioxidant properties as well as receptor-mediated
actions. Signaling pathways include membrane responses, cytoplasmic modula-
tion of kinases, nuclear receptor interactions, and improvement of mitochondrial
functions. This chapter focuses on the electrophysiological and the antiarrhythmic
properties of melatonin. The acute and chronic protective mechanisms of melatonin
will be analyzed with an emphasis on transmembrane potentials and intercel-
lular communication. An outstanding antifibrillatory effect makes melatonin a
novel antiarrhythmic agent worthy of further exploration in the path to clinical
Keywords: melatonin, arrhythmias, ventricular fibrillation, action potential,
connexin 43, melatonin receptors
. Introduction
“Nothing to do to save his life” says the Beatles song “Good morning, good
morning.” Ironically, cardiovascular mortality and life-threatening arrhythmias
show a circadian increase in the mornings, and chronoprotective agents are still
missing [1,2]. This chapter highlights the importance of melatonin as a potential
life-saving agent for the darkest nights (of antiarrhythmics drugs) and a brightest
The cardioprotective properties of melatonin are remarkable. Most of the
preclinical and clinical studies support the protective actions and the safety profile
of this indolamine [3, 4]. In this chapter, we briefly introduce the multitarget and
versatile properties of melatonin and general concepts of electrophysiology to
appreciate its potential as a promising antiarrhythmic agent. The second and third
sections of the chapters focus on acute and chronic melatonins antiarrhythmic
. Melatonin properties relevant to heart rhythms
Endogenous and pharmacological increases of melatonin concentrations protect
the cardiovascular system [3–11]. However, the relationships between the cardio-
vascular and circadian systems are highly complex and should not be interpreted in
reductionist ways [5, 1214]. Furthermore, our understanding of the pleiotropy of
melatonin, a highly preserved molecule of protection, is continuously expanding
[3–7, 10, 1524]. Therefore, we will focus on melatonin effects on heart rhythms.
Additional information regarding melatonin cardiovascular effects can be found
elsewhere and include direct actions in the heart, blood vessels, kidney, and other
regulatory mechanisms at the nervous, immune, and endocrine systems [11, 25,
26]. Only the electrophysiological information will be extracted from its protective
actions against risk factors like hypertension, metabolic syndrome, obesity, inflam-
mation, and pathologies like ischemia/reperfusion injury, infarction, drug-induced
cardiotoxicity, diabetic cardiomyopathy, and heart failure [8, 11, 21, 27].
Melatonin is amphipathic and pleiotropic. Melatonin can act on several targets
at cell membranes and at intracellular levels in almost any cell [28, 29]. For this
electrophysiological analysis, we present the following division of melatonin
mechanisms of action:
a. Antioxidant
b. Receptor activation
c. Improvement of mitochondrial functions
d. Ion channel modulation
1.1.1 Melatonin as an antioxidant
Melatonin protects against oxidants by several mechanisms. In fact, it has been
suggested that one of the main functions of melatonin in all living organisms is
to protect them from oxidative stress [30, 31]. Melatonin has a well-characterized
and extensively documented antioxidant capacity [31–37]. Melatonin is a powerful
antioxidant, with a potency of up to 10 times greater than vitamin E [38].
There are oxidants of different chemical nature. They can be free radicals or
non-radical reactive species [39, 40]. Free radicals—molecules with an unpaired
electron—are unstable, highly reactive, and often trigger chain reactions, which
propagate nearby molecular modifications. The most studied oxidants are the
reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive sulfur
species. Under physiological conditions, ROS/RNS act as second intracellular
messengers modulating signal transduction pathways [40, 41]. A delicate cellular
balance between the production and the removal of free radicals maintains low/
moderate concentrations. Oxidative stress occurs when oxidants increase above
healthy levels and represent a severe risk to the molecular integrity of lipids, pro-
teins, and DNA [39, 40]. Therefore, neutralization of reactive species by scavenger
molecules like melatonin is a chemical way of counteracting oxidative stress.
The main agent involved in oxidative damage is superoxide anion, but hydrogen
peroxide, hydroxyl radical, nitric oxide (NO), peroxynitrite, and nitroxyl also
participate in oxidative stress. The mitochondria are the main source of oxidizing
species during oxidative phosphorylation. Oxidants are also the product of the
activation of non-mitochondrial enzyme systems such as NADPH oxidase, xanthine
oxidase, and nitric oxide synthase [40–42].
Melatonin for a Healthy Heart Rhythm
DOI: hp://
Cells have antioxidants that prevent damage. An antioxidant is any substance
that significantly delays or prevents oxidation of lipids, proteins, or DNA [40].
Lipids are often used as target molecules because they are more reactive to oxidants
than proteins or DNA.Nonenzymatic antioxidants include reduced glutathione
(GSH), vitamins, and melatonin among others. Melatonin is five times more
effective than GSH as scavenger of the highly toxic hydroxyl radical [34]. The main
antioxidant enzymes are superoxide dismutase (SOD), catalase, thioredoxin, and
glutathione peroxidase [4044].
Melatonin efficiently prevents oxidative stress. The aromatic indole ring of
melatonin reduces and repairs electrophilic radicals acting as generous electron
donor. One molecule of melatonin can neutralize up to 10 toxic reagents, including
ROS, RNS, and other free radicals [7, 39, 4547]. In addition, several metabolites
formed when melatonin neutralizes harmful reagents are also antioxidants suggest-
ing that a cascade of reactions increases the efficacy of melatonin [28, 35, 4749].
Being a highly lipophilic and hydrophilic compound, melatonin crosses all mor-
phological barriers and acts not only in each cell but also within each subcellular
compartment. Additionally, melatonin increases the efficacy of vitamin E, vitamin
C, and GSH [33, 50]. Therefore, the elimination of free radicals can be carried out
by intracellular interactions independent of any receptor [36, 45, 51].
Melatonin stimulates antioxidant enzymes by acting on membrane, cytoplas-
mic, and nuclear receptors [39, 43, 52]. Low melatonin concentrations increase the
expression or activity of SOD, catalase, and glutathione peroxidase [43, 53].
Ion channels and many other proteins respond to oxidative stress [5458]. Amino
acid residues are the targets of ROS/RNS.Sulfur atoms like cysteine and methionine,
hydroxyl groups from tyrosine, or aromatic rings of histidine, phenylalanine, and
tryptophan are vulnerable to reactive species. Those that contain more cysteines are
more sensitive to changes because thiol groups (–SH), which exist as thiolates (–S)
at physiological pH, tend to react more quickly with ROS/RNS [59]. Many of these
proteins are involved in important biological reactions such as oxidative phosphory-
lation, metabolic regulation, and signal transduction [60, 61]. Oxidative stress can
increase late sodium currents through direct Na+ channel modification [62, 63]
and result in a prolonged action potential duration and arrhythmogenic triggers
known as early-after depolarizations (EAD) [64]. Several reviews describe the redox
regulation of calcium channel in cardiac myocytes including the ryanodine receptor
calcium, the IP3 receptor, and voltage-dependent L-type calcium channel [6569].
ROS and RNS affect the L-type Ca2+ channel Cav1.2 by regulation of cysteine
residues. However, calcium channel regulation by redox is controversial with reports
of increase and decrease of channel functions [66]. Voltage-gated potassium (Kv)
channel, mainly responsible for myocardial repolarization, is sensitive to oxidative
stress [58, 7072]. Sulfenic acid modification at a conserved cysteine residue of
Kv1.5 under prolonged oxidative stress can induce arrhythmia [58, 72].
.. Melatonin receptors
Melatonin has receptors in the cellular membranes, in the cytoplasm, and in the
nucleus. Melatonin membrane receptors express in several regions of the nervous
system and in almost all the organs including the heart, arteries, kidneys, liver, gas-
trointestinal tract, prostate gland, uterus, skin, and eyes [73]. Melatonin activates
two subtypes of G-protein-coupled receptors in the plasma membrane, named MT1
and MT2, according to the official IUPHAR nomenclature (previously called Mel1a
and Mel1b) [74]. Both receptors have high affinity to melatonin (Kd ~ 0.1 pM). In
2019, Stauch and Johansson reported the crystal structures of the human MT1 and
MT2 and set a solid base concerning ligand recognition for both receptors [75, 76].
Melatonin membrane receptors can exist as monomers, as well as dimers. The
MT1 homodimer forms 3- to 4-fold higher proportion than the MT2 homodimer
and the MT1/MT2 heterodimer. Nonmammalian vertebrates present a third low-
affinity receptor termed Mel1c, and a proposed mammalian homologous is the
orphan receptor GPR50 [74, 7779]. This orphan lost its properties to directly
interact with melatonin but shows an inhibitory interaction with MT1 receptors by
forming heterodimers. More recently, other orphans unable to bind melatonin like
GPR61, GPR62, and GPR135 showed a similar indirect inhibitory interaction with
MT2 receptors [80]. Other G-protein-coupled receptors like the serotonin receptor
5HT2c can interact with melatonin membrane receptors [79]. These interesting
interactions of membrane receptors are not further discussed in this chapter but
should be considered in future electrophysiological studies with melatonin.
The MT1 and MT2 inhibit adenylate cyclase-protein kinase A-CREB signaling
in target cells by pertussis toxin-sensitive Gαi, β, and γ and toxin-insensitive Gq,
β, and γ proteins [74, 79]. The MT1 also increases phosphorylation of mitogen-
activated protein kinase 1/2 (MAPK) and extracellular signal-regulated kinase 1/2
(ERK), as well as increasing potassium conductance through inwardly rectifying
(Kir3.x) channels. The later effect on potassium channels could be relevant to heart
electrophysiology since Kir3.x channels are highly expressed in cardiomyocytes
and usually coupled to acetylcholine and adenosine membrane receptors [81]. MT2
melatonin receptor activation inhibits both forskolin-stimulated cAMP production
and cGMP formation, activates protein kinase C (PKC) in the nervous system, and
decreases calcium-dependent dopamine release in the retina. Native functional
MT1/MT2 heterodimers in mouse rod photoreceptors mediate melatonins enhance-
ment of scotopic light sensitivity through phospholipase C and PKC pathways [82].
Several compounds interact with MT1 and MT2 receptors, but blocker luzindole
is the only with proven myocardial electrophysiological effects [83]. Luzindole and
4P-PDOT competitively block MT1 melatonin receptors at concentrations higher
than 300nM, and both are inverse agonists in systems with constitutively active
MT1 receptors [74, 79].
Melatonin interacts with several enzymes and intracellular proteins. The MT3
receptors is a quinone reductase 2 with an affinity in the nanomolar ranges [84].
This enzyme is possibly involved in the regulation of cellular oxidative status,
although the exact regulatory action of melatonin remains unclear [8487].
Furthermore, the electrophysiological effects of MT3 have not been reported yet.
Melatonin interacts with intracellular proteins such as calmodulin, calreticulin,
or tubulin [88]. The low-affinity interaction between melatonin and calmodulin
antagonizes the binding of Ca2+ and may be involved in its antioxidant action as
well as other electrophysiological signaling processes [89–96].
Melatonin increases the cytoplasmic levels of the heat shock protein 70in several
tissues including the heart [97102]. Further interaction with this chaperon will be
described in Section 3 of the chapter.
Melatonin is a ligand for the retinoid-related orphan nuclear hormone receptor
family (RZR/ROR) [74, 79]. RZR/RORα is expressed in a variety of organs, whereas
RZRβ is specific for the brain and retina [33]. ROR/RZR has been proposed to work
in coordination with the plasma membrane receptors MT1/MT2 to regulate gene
expression. We suggest a potential interaction with Vitamin D receptor (VDR),
which was elegantly confirmed in recent experiments [97, 103].
.. Melatonin improves mitochondrial functions
Mitochondria are critical for cellular metabolism and energy production.
They maintain life but also are gatekeepers of cell death [31, 104]. Mitochondria
Melatonin for a Healthy Heart Rhythm
DOI: hp://
produce up to 95% of the cellular energy in the form of ATP in aerobic cells
[105]. Mitochondrial oxidative phosphorylation uses a system of oxidoreductase
protein complexes (complexes I, II, III, and IV) to transfer electrons during ATP
production. Deficiencies in the electron transport chain can result in the leakage
of electrons and generate ROS/RNS [40, 41, 106, 107]. Oxidative stress decreases
respiratory complex activity, impairs electron transport system, and opens the
mitochondrial permeability transition pores leading to cell death [104, 106, 108].
Mitochondria are essentials for the protective actions of melatonin [51, 97, 106,
107, 109111]. The mechanisms involved include its antioxidant properties and
the preservation of complex I and III functions, inhibition of the opening of the
permeability transition pores, and the release of cytochrome c. Petrosillo etal.
demonstrate that melatonin prevents the opening of the mitochondrial permeabil-
ity transition pores and its deleterious consequences [51, 110, 112, 113]. We recently
reported that melatonin prevents mitochondrial edema, dilation of the ridges, high
activity of NADPH oxidase, and apoptosis [97]. Melatonin improves mitofusin-2,
which preserves the mitochondrial functional network and prevents apoptosis
[114]. The reduction of mitochondrial damage in the heart could be related to the
negative regulation of angiotensin II type 1 receptor (AT1) by melatonin [97]. The
induction of Hsp70 through melatonin is compatible with an additional mechanism
related to Tom 70, a translocase of the outer mitochondrial membrane [97, 115,
116]. The interaction of Hsp70 with Tom 70 initiates mitochondrial import pro-
cesses [116]. Tom 70 regulates melatonin-induced cardioprotection by preventing
mitochondrial deterioration and oxidative stress [97, 115].
Melatonins cardioprotection associates with an increase in the number of mito-
chondria and positive regulation of survival genes such as nicotinamide phosphori-
bosyl transferase and nicotinamide adenine dinucleotide-dependent deacetylases,
called sirtuins [117]. Particularly sirtuin-1 and sirtuin-3 are downstream mediators
of the cardioprotective actions of melatonin. Sirtuin-1can modulate fatty acid
oxidation, apoptosis, oxidative stress, and autophagy through deacetylation of
transduction factors like NF-κB, forkhead box class O, p53, peroxisome proliferator-
activated receptor alpha, thioredoxin-1, and Bcl-xL [117–121]. Sirtuin-3 is a family
member that is primarily located in the mitochondria and protects against inflam-
mation and diseases related to oxidative stress. Melatonin elevates sirtuin-3, stimu-
lates superoxide dismutase activity, and suppresses mitochondrial oxidative stress
[31, 117, 122, 123]. Additionally, melatonin protects nuclear and mitochondrial
DNA [122, 124, 125]. The multiple actions of melatonin provide potent protection
against mitochondrial-mediated lesions.
.. Melatonin modulates ion channels
Melatonin exerts its electrophysiological effects by multiple mechanisms. One
of the ways for melatonin to interact is through the modulation of ion channels.
Whether we consider its role as a drug or as a biological molecule, it should be taken
into account how melatonin has been considered an electrophysiological modulator
for many physiological and clinical conditions such as control of circadian rhythms,
regulation of arterial blood pressure and heart rate in mammals, sleep processes,
and antiaging, among others. Its role in the modulation of several ion channels is
crucial to understand the molecular mechanism underlying the electrophysiological
properties as an antiarrhythmic.
Melatonin regulates anionic and cationic selective channels by multiple
pathways, at different doses and time-dependent responses. It is important to
remember the wide spectrum of action this molecule has. For example, results
regarding the pathophysiology of lung fibrosis show that volume-regulated anion
currents do not respond to acute exposure of cells to melatonin in hypotonic solu-
tions [126]. However, when cells are pre-incubated with melatonin concentrations
from 1 to 100μM for 30–60min, the anionic currents in response to hypotonic-
ity are blunted in a dose-dependent manner. These time- and dose-dependent
responses could support the electrophysiological effect during regional ischemia
after 20–30minutes of melatonin exposure in isolated rat hearts, because during
ischemia cardiomyocyte swelling activates anionic currents, and melatonin down-
regulation of these currents is a potential explanation [127, 128]. Additionally,
these MT receptor interactions described in fibroblast deserve further evaluation
in myocardial tissue.
From the perspective of the interaction between melatonin and its target, it will
be crucial to increase the knowledge about the allosteric contact between melatonin
and an ion channel. For example, melatonin blocks the potassium channels (Kv1.3)
in a reversible manner through the interaction with different binding sites on the
human peripheral blood T lymphocytes [129]. However, the inhibitory effects
require high extracellular melatonin in the mM range [129]. Cardiomyocytes do not
express this specific potassium channel, but a homologous mechanism can exist for
other channels waiting to be reported.
Most of the information regarding the role and effect of melatonin in the
organisms has been described in the nervous system. One of the most popular
is melatonin-related circadian rhythm. In particular, how melatonin influences
circadian phase and electrical activity thanks to the interaction with Kir3.x channels
presents them as a therapeutic target for diseases related to circadian disruption
and melatonin signaling features [130]. In addition, the effects of melatonin in this
pacemaker of circadian rhythm could be due also to its modulation of inwardly
rectifying potassium channels (Kir3.1/Kir3.2) via MT1 receptors [131]. Moreover,
melatonin is also necessary for circadian regulation of sleep. This effect was
described to be driven by the suppression of GABAergic neurons by melatonin in
the lateral hypothalamus (crucial function for wakefulness), via interaction with
MT1 receptor in order to inactivate hyperpolarization-activated cyclic nucleotide-
gated channels [132].
Melatonin is a potential neuroprotective molecule thanks to its interaction in a
mitochondrial pathway involving the closing of permeability transition pore and
opening of ATP sensitive potassium channels (KATP) [133]. The opening of KATP
contributes to melatonin antiseizure effect [134]. The preventive actions on the
permeability transition pore have been reported in myocardial tissue as well [51,
112, 113]. However, opening of KATP channels with high concentrations of melato-
nin could be proarrhythmic [135, 136].
Melatonin modulates most of the voltage-activated calcium channel subtypes
(L, P, Q , N, and R) with different effects [137–141]. Melatonin inhibits voltage-
dependent calcium entry in cultured rat dorsal root ganglia neurons, regulates
calcium entry into pineal cells, and has dose-dependent inhibitory effects on free
[Ca2+]i in mouse brain cells [137]. Melatonin has no effect on voltage-activated
calcium channels in cultured human aortic smooth muscle cells [141]. Melatonin
accutelly increase L type calcium currents in chick cardiac membranes [140, 141].
An early study shows that melatonin downregulates voltage-sensitive calcium chan-
nels in the heart [142]. These results indicate that melatonin may have differnt acute
and chronic implications for normal cardiac physiology and for the pharmacological
manipulation of the heart [142].
Melatonin mediates vasodilation of cerebral arteries through the activation of
large-conductance Ca2+-activated K+ (BKCa) channels via both melatonin receptor-
dependent and melatonin receptor-independent modes, increasing BKCa channel
current density but not the KV channel current density [143]. Small-conductance
Melatonin for a Healthy Heart Rhythm
DOI: hp://
Ca2+-activated K (SK) channels are also modulated by the action of melatonin
[144]. Upregulation of SK channels plays a role in memory loss and indicates that
melatonin reverses memory deficits in rats by downregulation of SK1, SK2, and SK3
channels in their hippocampi [144].
Additional information was brought about KCNQ from the aorta and related
with vascular tone, and KCNH2in the left ventricle was associated with QT dura-
tion in rats where melatonin was able to prevent the increase in blood pressure and
change KCNQ and KCNH2 gene expression profiles [145].
Melatonin effects on connexin proteins will be extensively analyzed in the
second and third sections of the chapters for its proven relationship with both acute
and chronic antiarrhythmic effects of melatonin.
. Electrophysiology and arrhythmias
The heart pumps blood under a synchronized electrical control. Arrhythmias
are the electrical problems in the rhythm of the heart. The heartbeats may be faster
in the case of tachyarrhythmia and slower in bradyarrhythmia.
Fatal arrhythmic events follow a circadian pattern [2]. Arrhythmogenesis
decreases during nighttime when the melatonin levels increase 30 to 70 folds. Life-
threatening cardiac arrhythmias (ventricular tachycardia, ventricular fibrillation,
and sudden cardiac death) are more likely to occur in the morning after waking.
Arrhythmias also increase with age and heart diseases [146148].
Disturbances in membrane excitability or conduction cause arrhythmias.
Excitability manifests as action potentials and involves coordinated ion movements
across the cell membrane through ion channels, exchangers, and ATPases [149].
Conduction is the propagation of bioelectrical signal throughout the heart. Action
potentials automatically originate at the sinoatrial node, spread to the atria, and,
after a small delay in the atrioventricular node, rapidly and synchronously activate
the ventricles via the His-Purkinje system. Action potentials propagate from cell
to cell using low-resistance pathways known as gap junctions. Connexin proteins
assemble into intercellular channels at gap junctions. Connexin 43 (Cx43) is the most
abundant connexin in the heart [150]. Gap junctions couple the cells and allow the
flow of electrical current and small molecules. The largest accumulation of connex-
ins occurs in a specialized structure at the ends of cardiomyocytes called intercalated
discs. Cardiac propagation is anisotropic, particularly more rapid in the longitudinal
direction of the cell than in the transverse direction. The lateral borders of the
myocytes usually show variable amount gap junctions depending on age or disease.
Cardiovascular diseases are the leading cause of death in the world [151].
Most deaths occur suddenly [152]. Catastrophic sudden death events motivate
us to search for causes and possible solutions [153]. This is a great scientific and
social health challenge. The approaches of recent years have reduced the burden
of cardiovascular disease, but there is still much to improve [154]. A case occurs
with arrhythmias. The rhythm disorders motivated emergency interventions,
especially during the first hour of the manifestation of coronary heart disease.
Cardiopulmonary resuscitation, ambulances, and cardiodefibrillation were
response strategies to unexpected events. Unfortunately, they are still unexpected
due to the limited understanding of the causes at a level that would allow us to pre-
dict, avoid, or control the occurrence of an event [155]. In that sense, the strategies
that attempt to determine risks grew in order to establish a more efficient direction
of interventions [156, 157]. Today they allow us to expect more lethal events in
severely ill people. However, risk factors are still far from being effective and much
less efficient. The changes that occur in physiology as a result of exposure to differ-
ent risk factors would be one of the explanations [158].
. Acute antiarrhythmic mechanisms of melatonin
Melatonin acts at multiple electrophysiological levels due to its receptor-
dependent and receptor-independent mechanisms. In 1998, the seminal work of
Tan etal. highlighted the antiarrhythmic properties of melatonin [159]. During
the past two decades, our understanding of the pleiotropic action of melatonin
increased significantly.
The antiarrhythmic effect of melatonin was first attributed to its notable antiox-
idant properties, mainly because melatonin results were better than those obtained
with an ascorbic acid at concentration 10–500 times higher [159]. Numerous studies
confirmed antiarrhythmic protection and related it to its remarkable antioxidant
properties [160167].
Our research group corroborated the antiarrhythmic effect of melatonin in
isolated hearts of female rats, when administered continuously from the stage prior
to the onset of myocardial ischemia [127]. Notably, the antiarrhythmic protection
had a dose-dependent response, while the antioxidant capacity was the same for all
the doses studied. The preventive effect on the shortening of the action potential that
occurs between the 7th and 10th minute of the ischemia was another dose-dependent
variable found in our study. This led us to think that the antiarrhythmic mechanism
could be due to a lower heterogeneity in the repolarization of myocardial tissue that
diminishes the possibility of reentry circuits being formed and maintained. As previ-
ously mentioned, the time- and dose-dependent responses could be due to melatonin
inhibitory effect against swell-activated anionic currents [126128].
We recently showed that melatonin reduces arrhythmias when administered
during reperfusion, a useful timing for the clinical context of acute coronary syn-
dromes, because most therapies can only start close to the reperfusion period [168].
Melatonin showed protective mechanisms when administered to isolated hearts of
rats fed with fructose and spontaneously hypertensive rats. These animals show
greater activity of the enzyme NADPH oxidase, which is one of the main systems
for generating free radicals, and, therefore, higher levels of oxidative stress. The
antiarrhythmic effect was not affected in the models with greater oxidative stress,
and in all groups, it was accompanied by a temporary shortening of the duration
of the action potential during the first 3–5minutes of reperfusion. This result was
interpreted as a reduction in the ability to generate early and late postdepolariza-
tions. Self-limited arrhythmic events, such as ventricular extrasystoles, salvos, and
even non-sustained ventricular tachycardia, occurred in all experimental groups.
The main difference was that the hearts treated with melatonin did not show sus-
tained forms of arrhythmias, either sustained ventricular tachycardia or ventricular
fibrillation. These results (potential shortening and absence of sustained arrhyth-
mia) are difficult to reconcile with the mechanisms postulated for reentry circuits.
The same year of our publication of the antiarrhythmic protection of melatonin
administered in reperfusion, another group published that melatonin protects
against arrhythmias, by increasing the threshold to electrically induce sustained
ventricular fibrillation, by increasing the myocardial Cx43 by PKC in hyperten-
sive rats [169]. Melatonin prevented myocardial abnormalities of connexin and
improved cardiac conduction.
Based in these interesting results, we tested if melatonin could prevent
hypokalemia-induced ventricular fibrillation by Cx43 preservation [83]. The acute
administration of melatonin during low potassium perfusion reduced the incidence
of ventricular fibrillation and improved the recovery of sinus rhythm in those
hearts that, despite being treated with melatonin, developed sustained fibrilla-
tion. Protection was mediated by the activation of melatonin receptors and by the
prevention of dephosphorylation and lateralization of Cx43.
Melatonin for a Healthy Heart Rhythm
DOI: hp://
A brief explanation of the electrophysiological changes induced by hypokale-
mia will help to appreciate the relevance as antiarrhythmic. Severe hypokalemia
induces changes in ventricular repolarization, such as lengthening the QT interval,
prominent U waves, fusion of T and U waves associated with and increases risk of
arrhythmic death [83, 170, 171]. Our experimental model confirmed the lengthen-
ing of the QT interval and correlated with an increase in the duration of the action
potential [83]. Melatonin did not prevent the prolongation of the action potential
induced by hypokalemia when measured at 90% of repolarization but maintained
action potential duration at 50% of repolarization and made the membrane poten-
tial more stable, showing less after depolarization. Luzindole blunted both effects
of melatonin, suggesting the involvement of melatonin receptor activation in the
preservation of membrane potential.
Hypokalemia decreases NaK-ATPase activity and causes an intracellular Ca2+
overload that facilitates the development of delayed postdepolarizations through the
transient inward currents [172174]. Delayed postdepolarizations are considered
triggers of arrhythmias because they can initiate an action potential in isolated cells.
However, it is unlikely that an extra action potential can be initiated from a single
cell in the tissue due to a mismatch between the current source from the cell and the
current sink produced by the surrounding cells [175]. To overcome the source-sink
mismatch, there must be a reduced sink through intercellular decoupling or an
increase in the source through the synchronization of delayed postdepolarizations
between several adjacent cells. Both situations could be assumed based on the
results of anisotropic conduction studies and immunofluorescence imaging [83].
In fact, hypokalemia induces conduction abnormalities, increased amplitude
and duration of the P wave, a slight prolongation of the PR interval, atrioventricular
block, increased QRS duration, and cardiac arrest [173, 176]. We found all these
electrocardiographic disorders during our experimental model of hypokalemia [83].
Melatonin prevented the widening of the QRS and delayed activation of the poten-
tial for epicardial action. The latter could be considered as a substitute for conduc-
tion velocity in complex tissues such as ventricles, assuming unknown routes from
endocardial activation points that indicate the onset of QRS to epicardial myocytes
recorded with microelectrodes. These improvements in ventricular conduction were
related to Cx43 lateralization and dephosphorylation.
The lateralization of connexins has been detected in chronic atrial fibrillation,
cardiac hypertrophy, heart failure, and after myocardial infarction [21, 177179]. An
increase in the fraction of lateral connexins that form functional channels improves
transverse conduction velocity and contributes to the spread of the arrhythmogenic
impulse. High side-by-side lateralization can favor conduction blockage due to mis-
matches between the source and the sink [175, 180]. A unidirectional block can lead
to reentry circles that result in tachycardia or ventricular fibrillation [181]. Therefore,
the acute lateralization induced by hypokalemia is an important arrhythmogenic
factor [83]. It is noteworthy that melatonin prevented acute lateralization of Cx43.
Connexin 43 phosphorylation could lead to better coupling or uncoupling
depending on the target amino acid, but dephosphorylation is clearly associated
with uncoupling [21, 177, 182]. It is not yet known whether the dephosphorylation of
Cx43 during low potassium is the result of increased phosphatase activity and/or an
increase in phosphokinase or what are the intracellular mechanisms that prevented
dephosphorylation when treated with melatonin. Dramatic reductions in intercellular
communication due to the loss of phosphorylated Cx43 and the accumulation of non-
phosphorylated Cx43 were previously reported in other experimental models [177].
Our results could be relevant mainly in those situations in which acute hypo-
kalemia can be anticipated as in dialysis [183, 184]. Both QT interval and the QT
dispersion increase after dialysis. We propose that melatonin could make the heart
more resistant to arrhythmic events triggered by rapid changes in plasma electro-
lyte concentrations, regardless of a lack of effects on the ECG.In addition, those
dialysis patients also suffer from disorders in the circadian rhythms and low levels
of melatonin [185]. However, clinical translations of our results should be done with
caution, mainly because we use a high dose of melatonin administered directly to
the heart. Based on melatonins pharmacokinetics in humans, to achieve a similar
concentration in plasma to the one tested ex vivo, a dose 10 times higher the highest
intravenous dose tested until now should be administered [186, 187].
Melatonin has a remarkable antiarrhythmic activity that is carried out based
on actions dependent on and independent of receptor activation. To summarize
we propose that the antiarrhythmic effect of melatonin is mediated by receptor
activation beyond its outstanding antioxidant actions (Figure ). The shortening
of the action potential could be associated with the activation of MT1 melatonin
receptors, since they can regulate specific ion channels such as Kir3.1 channel. MT1
and MT2 receptors could indirectly modulate other electrophysiological effects
through intracellular signaling such as decreased cyclic adenosine monophosphate,
increased phospholipase C, and PKC activation.
. Chronic antiarrhythmic mechanisms of melatonin
Endogenous melatonin would be an intrinsically protective factor with thera-
peutic potential [188, 189]. Melatonin is a promising treatment for cardiovascular
diseases such as myocardial ischemia/reperfusion injury, hypertension, and heart
failure. It has been shown that melatonin levels were reduced in patients with acute
myocardial infarction and in patients undergoing primary coronary angioplasty
[190]. These findings suggest that melatonin could play an important role in
preventing ischemia/reperfusion heart injury. Indeed, reperfusion arrhythmias
increase in pinealectomized animals, suggesting a protective role of endogenous
physiological melatonin levels [163, 189].
Chronic melatonin supplementation, either in physiological or pharmacologi-
cal ranges, protects against arrhythmias [8, 21, 97, 163, 169, 189, 191, 192]. Beyond
the reported antioxidant properties of melatonin, it reduces severe ventricular
Figure 1.
Acute antiarrhythmic mechanisms of melatonin. The red arrows indicate stimulation, and the interrupted blue
lines indicate blockage.
Melatonin for a Healthy Heart Rhythm
DOI: hp://
arrhythmias by antifibrotic mechanisms, electrical remodeling, direct mitochon-
drial protection, myocardial Cx43 preservation via PKC signaling, and vitamin
D-HSP70/AT1 counterbalance (Figure ). Its cardioprotective properties persist in
relevant cardiovascular risk factor models like hypertensive, obese, and nephro-
pathic rats. The latter is interesting because most of the therapeutic interventions
postulated so far fail to be reproduced under risk factor conditions.
A preventive approach would be of great value in the face of unpredictable acute
arrhythmic events, especially if the intervention manages to avoid the most severe
and potentially lethal arrhythmias such as ventricular tachycardia and fibrillation.
Numerous efforts have been made in that direction. In the last quarter of the twentieth
century, several antiarrhythmic drugs were tried, but most of them showed a proar-
rhythmogenic profile or failed to reduce mortality [193196]. A time of great progress
was appreciated with the introduction of implantable cardiodefibrillators. However,
surgical intervention and high cost limit its population efficiency. A strategy to improve
the availability of preventive interventions is to select potential beneficiaries based
on their risk of serious events. This would compensate for potential side effects and
optimize the investment of resources. Other strategies, such as vaccines, are based on
achieving the greatest possible scope with the least number of interventions that attenu-
ate the severity of diseases. In the case of arrhythmias, we still have no clear “antiar-
rhythmic vaccine.” Therefore, risk-oriented strategies would be an acceptable approach.
From a preventive point of view, the pleiotropic protection mechanisms of
melatonin could effectively limit the arrhythmic complications associated with
hypertension [21, 169]. Arterial hypertension causes vascular deterioration, over-
loads the heart, and predisposes to a greater number of arrhythmic events. More
than five decades ago, it was reported that surgical removal of the pineal gland,
aprocedure that essentially eliminates circulating levels of melatonin, was followed
by a slow but persistent increase in blood pressure in rats [197]. This finding has
been confirmed in several subsequent studies [11]. In addition, daily treatment of
pinealectomized rats with melatonin attenuated the elevation in blood pressure
Figure 2.
Antiarrhythmic mechanisms of chronic melatonin administration. Extracellular lines represent reduced fibrosis
after melatonin treatment. The red arrows indicate stimulation and blue ones show blockage. The green arrow
marks direct mitochondrial protection.
that accompanies pinealectomy [198, 199]. Potentially related to these experimental
findings are those observational studies in humans that document an age-related
gradual increase in blood pressure [7]. Of special interest is that the ability of the
pineal gland to produce melatonin is compromised during aging so that the levels of
melatonin in the blood at night gradually decrease [28, 30, 110]. An implication of
these findings is that the loss of melatonin during aging can contribute to gradual
hypertension and arrhythmias.
The structural remodeling of the myocardium that follows hypertension (mainly
cardiomyocyte hypertrophy and fibrosis) is accompanied by changes in the expres-
sion, distribution and function of the ionic channels of the cell membrane and the
intercellular channels constituted by Cx43 [21, 191, 200]. Remodeling predisposes
to life-threatening ventricular tachycardia and ventricular fibrillation by early or
late postdepolarization and reentry. Melatonin prevents changes in ventricular
redistribution of Cx43 and reduces arrhythmia inducibility [8, 21, 147, 191].
Another chronodisruptor that increases arrhythmic risk are kidney diseases.
Chronic kidney diseases (CKD) alter the nocturnal secretion of melatonin [185,
201]. Melatonin levels correlate negatively with the intrarenal activity of renin-
angiotensin II-aldosterone system (RAAS) [202]. Melatonin improves intrarenal
RAAS in the 5/6 nephrectomy rat model and reduces blood pressure, oxidative
stress, and interstitial fibrosis in the remaining kidneys [203].
Renal diseases cause cardiovascular and electrolytic remodeling that increases
the risk of arrhythmias [204206]. Cardiovascular events occur more frequently
in patients with chronic kidney disease. Ventricular arrhythmias are particularly
prevalent among patients with CKD, even when those patients do not suffer from
any electrolyte imbalance [207]. The risk of mortality also increases in patients with
CKD who suffer from an acute coronary syndrome [208]. We demonstrated that
unilateral ureteral obstruction caused a cardiac remodeling that was accompanied
by an increase in reperfusion arrhythmias [209].
The electrophysiological properties of chronic melatonin deserve attention, due
to their relevance for cardiorenal situations with high arrhythmic risk and lack of
treatments. We recently confirmed the antifibrotic, antiapoptotic, and antioxidant
effects of melatonin and linked them to an HSP 70-VDR/AT1 counterbalance which
prevents kidney damage and arrhythmogenic remodeling of the heart [97].
In renal and myocardial tissue, melatonin increased HSP 70 and VDR and
decreased AT1 and fibrosis. Melatonin increases HSP 70 and protects the liver of
rats exposed to toluene from cytotoxicity induced by oxidative stress [100]. HSP 70
regulates antioxidant responses to cellular oxidative stress and reduces NADPH oxi-
dase activity and expression [210]. We demonstrated a myocardial increase in HSP
70in rats treated with melatonin. HSP 70 induces VDR and facilitates intracellular
localization of active vitamin D metabolites and transactive VDRs [209, 211, 212].
Nuclear melatonin receptors, as members of retinoid-related orphan receptors,
may interact and prevent degradation of VDR [97, 103]. Expression of myocardial
VDR links chronic kidney disease with cardiovascular disease due to the reduction
in VDR that amplifies the effects of angiotensin [212]. Melatonin decreases renal
and myocardial overexpression of AT1 [97]. It is well documented that the AT1
pathway leads to myocardial fibrosis during CKD [97]. As previously suggested,
the low expression of AT1 through VDR induction could be a consequence of HSP
70-mediated cellular protection [213]. Angiotensin II exerts a tonic modulation of
melatonin synthesis by influencing the activity of tryptophan hydroxylase through
AT1 supporting the postulated feedback (or reciprocal regulation) between AT1
and melatonin [97, 202].
Additionally, the mitochondrial dynamics relates to the RAAS.We show that
melatonin prevents mitochondrial edema, high activity of NADPH oxidase, and
Melatonin for a Healthy Heart Rhythm
DOI: hp://
apoptosis. In this sense, the reduction of mitochondrial damage melatonin could be
related to the negative regulation of AT1. The induction of HSP 70 through melato-
nin is compatible with an additional mechanism related to Tom 70. Furthermore,
Tom 70 regulates melatonin-induced protection against myocardial infarction
[115, 116]. All these data allow us to assume that the induction of HSP 70 by melato-
nin and the reduction of AT1 are critical components of the cellular stress response.
We attribute the higher vulnerability to ventricular fibrillation during reperfu-
sion in the kidney disease rat model to the prooxidative and profibrotic changes that
accompanied the increase in AT1 and the decrease in HSP 70 [97, 209]. Myocardial
oxidative stress—particularly in the mitochondria—and fibrosis are well-known
proarrhythmic substrates [55, 71]. Free radicals act as triggers for the beginning of
arrhythmic events. The persistence of high-frequency rhythms requires reentry
circuits [214]. Altered conduction and shortening of the action potential contribute
to the complex reentry mechanisms involved in ventricular fibrillation.
Melatonin protection against myocardial remodeling induced by kidney disease
is one of the factors that protect against ventricular fibrillation. Chronic melatonin
prolongs the action potential duration and hyperpolarizes the cardiomyocytes. These
changes are the first report of myocardial action potential modifications by chronic
administration of melatonin. Opening of Kir3.x channels by melatonin receptor
activation could explain hyperpolarization [131]. The action potential lengthening
is harder to explain because melatonin activates currents involved in the action
potential repolarization and the only inhibitory effect of melatonin against outward
potassium currents was described in neurons [90, 129, 130, 215217]. As previously
mentioned, the downregulation of volume-activated anionic currents can explain
attenuated response to action potential shortening induced by ischemia [126].
A synthesis of the mechanisms of protection of chronic treatment of melatonin
cardiovascular complications is outlined in Figure . We focus our attention on
the preventive effects of melatonin against the alteration of Cx43, mitochondrial
oxidant capacity, and membrane potentials. In addition, modulation of the AT1 and
VDR receptors related to the increase of HSP 70 contributes to the cardioprotective
effects of melatonin.
. Conclusions
Melatonin is the rhythmic protector of healthy heart rhythm and a promising
preventive agent against ventricular fibrillation, the most lethal and disorganized
heart rhythm. Pleotropic effects of melatonin make it an exceptional acute and
chronic antiarrhythmic.
This work was supported by grant by ESC research grant funded by the
European Society of Cardiology, by ERC-2014-StG 638284 funded by the European
Research Council, by project DPI2016-75458-R funded by MINECO (Spain) and
FEDER, and by Reference Group BSICoS T39-17R and project LMP124-18 funded
by Gobierno de Aragón and FEDER 2014-2020 “Building Europe from Aragón.
Conflict of interest
The authors declare no conflict of interest.
Author details
Natalia JorgelinaPrado1,2, MargaritaSegovia-Roldan2, Emiliano RaúlDiez1,2*
1 Medical Faculty, CONICET, IMBECU, National University of Cuyo, Mendoza,
2 I3A, Universidad de Zaragoza, IIS Aragón and CIBER-BBN, Zaragoza, Spain
*Address all correspondence to:
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms
of the Creative Commons Attribution License (
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Melatonin for a Healthy Heart Rhythm
DOI: hp://
[1] Priori SG, Blomström-Lundqvist C,
Mazzanti A, Blom N, Borggrefe M,
Camm J, etal. 2015 ESC guidelines
for the management of patients
with ventricular arrhythmias and
the prevention of sudden cardiac
death. European Heart Journal.
[2] Black N, D’Souza A, Wang Y,
Piggins H, Dobrzynski H, Morris G,
etal. Circadian rhythm of cardiac
electrophysiology, arrhythmogenesis,
and the underlying mechanisms. Heart
Rhythm. 2019;:298-307
[3] Baltatu OC, Senar S, Campos LA,
Cipolla-Neto J.Cardioprotective
melatonin: Translating from proof-
of-concept studies to therapeutic use.
International Journal of Molecular
Sciences. 2019;:4342
[4] Zhou H, Ma Q ,Zhu P,Ren J,
Reiter RJ, Chen Y.Protective role
of melatonin in cardiac ischemia-
reperfusion injury: From pathogenesis
to targeted therapy. Journal of Pineal
Research. 2018;:e12471
[5] Pliss MG, Kuzmenko NV, Rubanova NS,
Tsyrlin VA.Dose-dependent mechanisms
of melatonin on the functioning of
the cardiovascular system and on
the behavior of normotensive rats of
different ages. Advances in Gerontology.
[6] Jiki Z, Lecour S, Nduhirabandi F.
Cardiovascular benefits of dietary
melatonin: A myth or a reality?
Frontiers in Physiology. 2018;:528
[7] Favero G, Franceschetti L, Buffoli B,
Moghadasian MH, Reiter RJ, Rodella LF,
etal. Melatonin: Protection against
age-related cardiac pathology. Ageing
Research Reviews. 2017;:336-349
[8] Egan Benova T, Viczenczova C,
Szeiffova Bacova B, Knezl V, Dosenko V,
Rauchova H, etal. Obesity-associated
alterations in cardiac connexin-43
and PKC signaling are attenuated by
melatonin and omega-3 fatty acids in
female rats. Molecular and Cellular
Biochemistry. 2019;:191-202
[9] Singhanat K, Apaijai N, Chattipakorn
SC, Chattipakorn N.Roles of melatonin
and its receptors in cardiac ischemia–
reperfusion injury. Cellular and Molecular
Life Sciences. 2018;:4125-4149
[10] Pandi-Perumal SR, BaHammam AS,
Ojike NI, Akinseye OA, Kendzerska T,
Buttoo K, etal. Melatonin and human
cardiovascular disease. Journal of
Cardiovascular Pharmacology and
Therapeutics. 2017;:122-132
[11] Prado NJ, Ferder L, Manucha W,
Diez ER.Anti-inflammatory effects of
melatonin in obesity and hypertension.
Current Hypertension Reports.
[12] Crnko S, Du Pré BC, Sluijter JPG,
Van Laake LW.Circadian rhythms and
the molecular clock in cardiovascular
biology and disease. Nature Reviews.
Cardiology. 2019;:437-447
[13] Rana S, Prabhu SD, Young ME.
Chronobiological influence over
cardiovascular function. Circulation
Research. 2020;:258-279
[14] Martino TA, Young ME.Influence
of the cardiomyocyte circadian clock on
cardiac physiology and pathophysiology.
Journal of Biological Rhythms. 2015;:
[15] Zhou H, Yue Y, Wang J, Ma Q ,
Chen Y.Melatonin therapy for diabetic
cardiomyopathy: A mechanism
involving Syk-mitochondrial complex
I-SERCA pathway. Cellular Signalling.
[16] Yang Y, Sun Y, Yi W, Li Y, Fan C,
Xin Z, etal. A review of melatonin as a
suitable antioxidant against myocardial
ischemia-reperfusion injury and
clinical heart diseases. Journal of Pineal
Research. 2014;:357-366
[17] Sun H, Gusdon AM, Qu S.Effects of
melatonin on cardiovascular diseases.
Current Opinion in Lipidology.
[18] Han D, Wang Y, Chen J,Zhang J,
Yu P, Zhang R, etal. Activation of
melatonin receptor 2 but not melatonin
receptor 1 mediates melatonin-conferred
cardioprotection against myocardial
ischemia/reperfusion injury. Journal of
Pineal Research. 2019;:e12571
[19] Hsu C-N, Huang L-T, Tain Y-L.
Perinatal use of melatonin for offspring
health: Focus on cardiovascular and
neurological diseases. International
Journal of Molecular Sciences.
[20] Li K, Hu F, Xiong W, Wei Q , Liu FF.
Network-based transcriptomic analysis
reveals novel melatonin-sensitive genes
in cardiovascular system. Endocrine.
[21] Egan Benova T, Szeiffova
Bacova B,Viczenczova C, Diez E,
Barancik M, Tribulova N.Protection
of cardiac cell-to-cell coupling
attenuate myocardial remodeling
and proarrhythmia induced by
hypertension. Physiological Research.
2016;(Suppl 1):S29-S42
[22] Zhai M, Li B, Duan W, Jing L,
Zhang B, Zhang M, etal. Melatonin
ameliorates myocardial ischemia
reperfusion injury through SIRT3-
dependent regulation of oxidative
stress and apoptosis. Journal of Pineal
Research. 2017;:e12419
[23] Nduhirabandi F,Maarman G,
Nduhirabandi F, Maarman GJ. Melatonin
in heart failure: A promising therapeutic
strategy? Molecules. 2018;:1819
[24] Reiter RJ, Tan DX, Paredes SD,
Fuentes-Broto L.Beneficial effects of
melatonin in cardiovascular disease.
Annals of Medicine. 2010;:279-285
[25] Pechanova O, Paulis L,Simko F.
Peripheral and central effects of
melatonin on blood pressure regulation.
International Journal of Molecular
Sciences. 2014;:1792017937
[26] Baltatu OC, Amaral FG,
Campos LA, Cipolla-Neto J.Melatonin,
mitochondria and hypertension.
Cellular and Molecular Life Sciences.
[27] Lahera V, de Las HN, López-
Farré A, Manucha W, Ferder L.Role
of mitochondrial dysfunction in
hypertension and obesity. Current
Hypertension Reports. 2017;:11
[28] Pandi-Perumal SR.Melatonin:
Biological Basis of its Function in Health
and Disease. CRC Press; 2005. ISBN
[29] Hardeland R, Cardinali DP,
Srinivasan V, Spence DW, Brown GM,
Pandi-Perumal SR.Melatonin-a pleiotropic,
orchestrating regulator molecule. Progress
in Neurobiology. 2011;:350-384
[30] Poeggeler B, Reiter RJ, Tan D-X,
Chen L-D, Manchester LC.Melatonin,
hydroxyl radical-mediated oxidative
damage, and aging: A hypothesis. Journal
of Pineal Research. 1993;:151-168
[31] Reiter RJ, Rosales-Corral S, Tan DX,
Jou MJ, Galano A, Xu B.Melatonin as
a mitochondria-targeted antioxidant:
One of evolutions best ideas.
Cellular and Molecular Life Sciences.
[32] Galano A, Tan DX, Reiter RJ.
Melatonin as a natural ally against
oxidative stress: A physicochemical
examination. Journal of Pineal
Research. 2011;:1-16
Melatonin for a Healthy Heart Rhythm
DOI: hp://
[33] Galano A, Reiter RJ.Melatonin
and its metabolites vs oxidative stress:
From individual actions to collective
protection. Journal of Pineal Research.
[34] Galano A.On the direct scavenging
activity of melatonin towards hydroxyl
and a series of peroxyl radicals. Physical
Chemistry Chemical Physics (PCCP).
[35] Galano A, Tan DX, Reiter RJ.On
the free radical scavenging activities
of melatonins metabolites, AFMK
and AMK.Journal of Pineal Research.
[36] Manchester LC, Coto-Montes A,
Boga JA, Andersen LPH, Zhou Z,
Galano A, etal. Melatonin: An ancient
molecule that makes oxygen
metabolically tolerable. Journal of
Pineal Research. 2015;:403-419
[37] Reiter RJ, Tan DX, Galano A.
Melatonin: Exceeding expectations.
Physiology. 2014;:325-333
[38] Reiter RJ, Tan DX.Melatonin: A
novel protective agent against oxidative
injury of the ischemic/reperfused heart.
Cardiovascular Research. 2003;:10-19
[39] Reiter RJ, Mayo JC, Tan D-X,
Sainz RM, Alatorre-Jimenez M, Qin L.
Melatonin as an antioxidant: Under
promises but over delivers. Journal of
Pineal Research. 2016;:253-278
[40] Forman HJ.Redox signaling: An
evolution from free radicals to aging.
Free Radical Biology & Medicine.
[41] Dröge W.Free radicals in the
physiological control of cell function.
Physiological Reviews. 2002;:47-95
[42] Radi R.Oxygen radicals, nitric
oxide, and peroxynitrite: Redox
pathways in molecular medicine.
Proceedings of the National Academy
of Sciences of the United States of
America. 2018;:5839-5848
[43] Rodriguez C, Mayo JC, Sainz RM,
Antolin I, Herrera F, Martin V, etal.
Regulation of antioxidant enzymes: A
significant role for melatonin. Journal of
Pineal Research. 2004;:1-9
[44] Afanas’Ev I.ROS and RNS signaling
in heart disorders: Could antioxidant
treatment be successful? Oxidative
Medicine and Cellular Longevity.
[45] Yang Y, Sun Y, Yi W, Li Y, Fan C,
Xin Z, etal. A review of melatonin as a
suitable antioxidant against myocardial
ischemia-reperfusion injury and
clinical heart diseases. Journal of Pineal
Research. 2014;:357-366
[46] Brazão V, Santello FH, Colato RP,
Mazotti TT, Tazinafo LF, MPA T,
etal. Melatonin: Antioxidant and
modulatory properties in age-related
changes during Trypanosoma cruzi
infection. Journal of Pineal Research.
[47] Tan D-X, Manchester LC,
Terron MP, Flores LJ, Reiter RJ.One
molecule, many derivatives: A never-
ending interaction of melatonin
with reactive oxygen and nitrogen
species? Journal of Pineal Research.
[48] Tan DX, Hardeland R,
Manchester LC, Paredes SD, Korkmaz A,
Sainz RM, etal. The changing biological
roles of melatonin during evolution:
From an antioxidant to signals of
darkness, sexual selection and fitness.
Biological Reviews. 2010;:607-623
[49] Tengattini S,Reiter RJ,Tan DX,
Terron MP, Rodella LF, Rezzani R.
Cardiovascular diseases: Protective
effects of melatonin. Journal of Pineal
Research. 2008;:16-25
[50] Dominguez-Rodriguez A,
Abreu-Gonzalez P,Garcia-Saiz MM,
Aldea-Perona A,delaTorre JM,
Garcia-Camarero T, etal. Cardio-
protection with melatonin in the acute
myocardial infarction: Awaiting results
of MARIA trial? International Journal of
Cardiology. 2015;:54-55
[51] Petrosillo G, Colantuono G, Moro N,
Ruggiero FM, Tiravanti E, Di Venosa N,
etal. Melatonin protects against heart
ischemia-reperfusion injury by inhibiting
mitochondrial permeability transition
pore opening. The American Journal
of Physiology-Heart and Circulatory
Physiology. 2009;:H1487-H1493
[52] Yeung HM, Hung MW, Lau CF,
Fung ML.Cardioprotective effects of
melatonin against myocardial injuries
induced by chronic intermittent hypoxia
in rats. Journal of Pineal Research
[53] Yanar K, Simsek B, Çakatay U.
Integration of melatonin related redox
homeostasis, aging, and circadian
rhythm. Rejuvenation Research.
[54] Sovari AA.Cellular and molecular
mechanisms of arrhythmia by oxidative
stress. Cardiology Research and
Practice. 2016;:1-7
[55] Yang KC, Kyle JW,Makielski JC,
Dudley SC.Mechanisms of sudden
cardiac death: Oxidants and
metabolism. Circulation Research.
[56] Zhou L, Cortassa S, Wei AC, Aon MA,
Winslow RL, O’Rourke B.Modeling
cardiac action potential shortening
driven by oxidative stress-induced
mitochondrial oscillations in guinea pig
cardiomyocytes. Biophysical Journal.
[57] Akbarali HI.Oxidative stress
and ion channels. In Systems Biology
of Free Radicals and Antioxidants;
Springer-Verlag Berlin Heidelberg, 2012;
pp.355-373; ISBN 9783642300189
[58] Bhuyan R, Chakraborti S.Oxidative
stress and modulation of cardiac Kv1.5
channel. In: Oxidative Stress in Heart
Diseases. Singapore: Springer; 2019.
[59] Poole LB.The basics of thiols
and cysteines in redox biology and
chemistry. Free Radical Biology &
Medicine. 2015;:148-157
[60] Chouchani ET,James AM,
Methner C, Pell VR, Prime TA,
Erickson BK, etal. Identification and
quantification of protein S -nitrosation
by nitrite in the mouse heart during
ischemia. The Journal of Biological
Chemistry. 2017;:14486-14495
[61] Smith BC, Marletta MA.Mechanisms
of S-nitrosothiol formation and
selectivity in nitric oxide signaling.
Current Opinion in Chemical Biology.
[62] Ward CA, Giles WR.Ionic
mechanism of the effects of
hydrogen peroxide in rat ventricular
myocytes. The Journal of Physiology.
[63] Ma JH, Luo AT, Zhang PH.Effect of
hydrogen peroxide on persistent sodium
current in Guinea pig ventricular
myocytes. Acta Pharmacologica Sinica.
[64] Light PE, Wallace CHR,Dyck JRB.
Constitutively active adenosine
monophosphate-activated protein
kinase regulates voltage-gated sodium
channels in ventricular myocytes.
Circulation. 2003;:1962-1965
[65] Mazzocchi G, Sommese L,
Palomeque J, Felice JI, Di Carlo MN,
Fainstein D, etal. Phospholamban
ablation rescues the enhanced
propensity to arrhythmias of mice with
CaMKII-constitutive phosphorylation
Melatonin for a Healthy Heart Rhythm
DOI: hp://
of RyR2 at site S2814. The Journal of
Physiology. 2016;:3005-3030
[66] Bogeski I,Kappl R,Kummerow C,
Gulaboski R, Hoth M,Niemeyer BA.
Redox regulation of calcium ion
channels: Chemical and physiological
aspects. Cell Calcium. 2011;:407-423
[67] Bogeski I, Niemeyer BA.Redox
regulation of ion channels. Antioxidants
& Redox Signaling. 2014;:859-862
[68] Zima AV, Blatter LA.Redox
regulation of cardiac calcium channels
and transporters. Cardiovascular
Research. 2006;:310-321
[69] Sag CM, Wagner S, Maier LS.Role
of oxidants on calcium and sodium
movement in healthy and diseased
cardiac myocytes. Free Radical Biology
& Medicine. 2013;:338-349
[70] Yang K-C, Kyle JW, Makielski JC,
Dudley SC.Mechanisms of sudden
cardiac death. Circulation Research.
[71] Jeong E-M, Liu M, Sturdy M, Gao G,
Varghese ST, Sovari AA, etal. Metabolic
stress, reactive oxygen species, and
arrhythmia. Journal of Molecular and
Cellular Cardiology. 2012;:454-463
[72] Svoboda LK, Reddie KG,
Zhang L, Vesely ED, Williams ES,
Schumacher SM, etal. Redox-sensitive
sulfenic acid modification regulates
surface expression of the cardiovascular
voltage-gated potassium channel Kv1.5.
Circulation Research. 2012;:842-853
[73] Slominski RM, Reiter RJ,
Schlabritz-Loutsevitch N, Ostrom RS,
Slominski AT.Melatonin membrane
receptors in peripheral tissues:
Distribution and functions. Molecular
and Cellular Endocrinology.
[74] Jockers R, Delagrange P,
Dubocovich ML, Markus RP, Renault N,
Tosini G, etal. Update on melatonin
receptors: IUPHAR review 20.
British Journal of Pharmacology.
[75] Stauch B,Johansson LC,
McCorvy JD, Patel N, Han GW,
Huang XP, etal. Structural basis
of ligand recognition at the human
MT1 melatonin receptor. Nature.
[76] Johansson LC,Stauch B,
McCorvy JD, Han GW, Patel N,
Huang XP, etal. XFEL structures of the
human MT2 melatonin receptor reveal
the basis of subtype selectivity. Nature.
[77] Benleulmi-Chaachoua A,
Chen L, Sokolina K, Wong V, Jurisica I,
Emerit MB, etal. Protein interactome
mining defines melatonin MT1
receptors as integral component of
presynaptic protein complexes of
neurons. Journal of Pineal Research.
[78] Jockers R, Maurice P, Boutin JA,
Delagrange P.Melatonin receptors,
heterodimerization, signal transduction
and binding sites: What’s new?
British Journal of Pharmacology.
[79] Cecon E,Oishi A,Jockers R.
Melatonin receptors: Molecular
pharmacology and signalling in the
context of system bias. British Journal of
Pharmacology. 2018;:3263-3280
[80] Oishi A, Karamitri A, Gerbier R,
Lahuna O, Ahmad R, Jockers R.Orphan
GPR61, GPR62 and GPR135 receptors
and the melatonin MT 2 receptor
reciprocally modulate their signaling
functions. Scientific Reports.
[81] Hibino H,Inanobe A,Furutani K,
Murakami S, Findlay I, Kurachi Y.
Inwardly rectifying potassium channels:
Their structure, function, and
physiological roles. Physiological
Reviews. 2010;:291-366
[82] Baba K, Benleulmi-Chaachoua A,
Journé AS, Kamal M, Guillaume JL,
Dussaud S, etal. Heteromeric MT1/
MT2 melatonin receptors modulate
photoreceptor function. Science
Signaling. 2013;:ra89-ra89
[83] Prado NJ, Egan Beňová T, Diez ER,
Knezl V, Lipták B, Ponce Zumino AZ,
etal. Melatonin receptor activation
protects against low potassium-induced
ventricular fibrillation by preserving
action potentials and connexin-43
topology in isolated rat hearts. Journal
of Pineal Research. 2019;:e12605
[84] Boutin JA, Ferry G.Is there
sufficient evidence that the melatonin
binding site MT3 is quinone reductase
2? The Journal of Pharmacology
and Experimental Therapeutics.
[85] Zhang HM, Zhang Y.Melatonin:
A well-documented antioxidant with
conditional pro-oxidant actions. Journal
of Pineal Research. 2014;:131-146
[86] Boutin JA, Marcheteau E, Hennig P,
Moulharat N, Berger S, Delagrange P,
etal. MT3/QR2 melatonin binding site
does not use melatonin as a substrate
or a co-substrate. Journal of Pineal
Research. 2008;:524-531
[87] Mailliet F, Ferry G, Vella F,
Berger S, Cogé F, Chomarat P, etal.
Characterization of the melatoninergic
MT3 binding site on the NRH:Quinone
oxidoreductase 2 enzyme. Biochemical
Pharmacology. 2005;:74-88
[88] Pandi-Perumal SR,Trakht I,
Srinivasan V, Spence DW,
Maestroni GJMM, Zisapel N, etal.
Physiological effects of melatonin:
Role of melatonin receptors and signal
transduction pathways. Progress in
Neurobiology. 2008;:335-353
[89] Gonano LA, Sepúlveda M, Rico Y,
Kaetzel M, Valverde CA, Dedman J,
etal. Calcium-calmodulin kinase II
mediates digitalis-induced arrhythmias.
Circulation: Arrhythmia and
Electrophysiology. 2011;:947-957
[90] Squecco R,Tani A, Zecchi-Orlandini
S, Formigli L, Francini F. Melatonin
affects voltage-dependent calcium
and potassium currents in MCF-7
cell line cultured either in growth or
differentiation medium. European
Journal of Pharmacology. 2015;:40-52
[91] Wong R, Steenbergen C, Murphy E.
Mitochondrial permeability transition
pore and calcium handling. In:
Mitochondrial Bioenergetics. Methods
in Molecular Biology (Methods and
Protocols). Humana Press. 2012;.
ISBN 978-1-61779-381-3
[92] Valverde CA, Kornyeyev D,
Mattiazzi AR, Escobar AL.Reperfusion
after ichemia causes cytosolic calcium
overload due to rapid calcium release
from the sarcoplasmic reticulum.
Biophysical Journal. 2009;:550a
[93] Yeung HM, Hung MW,
Fung ML.Melatonin ameliorates
calcium homeostasis in myocardial
and ischemia-reperfusion injury in
chronically hypoxic rats. Journal of
Pineal Research. 2008;:373-382
[94] Valverde CA, Mattiazzi A,
Escobar AL.Camkii exacerbates calcium
waves during reperfusion of
ischemic heart. Biophysical Journal.
[95] Baumeister P, Quinn TA.Altered
calcium handling and ventricular
arrhythmias in acute ischemia.
Clinical Medicine Insights: Cardiology.
[96] terKeurs HEDJ, Boyden PA.Calcium
and Arrhythmogenesis. Physiological
Reviews. 2007;:457-506
Melatonin for a Healthy Heart Rhythm
DOI: hp://
[97] Prado NJ, Casarotto M, Calvo JP,
Mazzei L, Ponce Zumino AZ, García IM,
etal. Antiarrhythmic effect linked
to melatonin cardiorenal protection
involves AT 1 reduction and Hsp70-VDR
increase. Journal of Pineal Research.
[98] Xu W, Cai S-YY, Zhang Y, Wang Y,
Ahammed GJ, Xia X-JJ, etal. Melatonin
enhances thermotolerance by promoting
cellular protein protection in tomato
plants. Journal of Pineal Research.
[99] Rezzani R, Rodella LF,Bonomini F,
Tengattini S, Bianchi R,Reiter RJ.
Beneficial effects of melatonin in
protecting against cyclosporine
A-induced cardiotoxicity are receptor
mediated. Journal of Pineal Research.
[100] Tas U, Ogeturk M, Kuloglu T,
Sapmaz HI, Kocaman N, Zararsiz I, etal.
HSP70 immune reactivity and TUNEL
positivity in the liver of toluene-inhaled
and melatonin-treated rats. Toxicology
and Industrial Health. 2013;:514-522
[101] Yoon YM, Kim HJ, Lee JH,
Lee SH.Melatonin enhances mitophagy
by upregulating expression of heat
shock 70 kDa protein 1L in human
mesenchymal stem cells under oxidative
stress. International Journal of
Molecular Sciences. 2019;:4545
[102] Motawi TK,Ahmed SA, A
Hamed M, El-Maraghy SA, M Aziz W.
Melatonin and/or rowatinex attenuate
streptozotocin-induced diabetic renal
injury in rats. Journal of Biomedical
Research. 2019;:113-121
[103] Fang N, Hu C, Sun W, Xu Y, Gu Y,
Wu L, etal. Identification of a novel
melatonin-binding nuclear receptor:
Vitamin D receptor. Journal of Pineal
Research. 2020;:e12618
[104] Morciano G, Giorgi C,
Bonora M, Punzetti S, Pavasini R,
Wieckowski MR, etal. Molecular identity
of the mitochondrial permeability
transition pore and its role in ischemia-
reperfusion injury. Journal of Molecular
and Cellular Cardiology. 2015;:142-153
[105] Hacışevki A, Baba B.An overview
of melatonin as an antioxidant
molecule: a biochemical approach. In:
Melatonin—Molecular Biology, Clinical
and Pharmaceutical Approaches. Rijeka:
IntechOpen; 2018
[106] Ganie SA, Dar TA, Bhat AH,
Dar KB, Anees S, Zargar MA, etal.
Melatonin: A potential anti-oxidant
therapeutic agent for mitochondrial
dysfunctions and related disorders.
Rejuvenation Research. 2016;:21-40
[107] Das N, Mandala A, Naaz S,
Giri S, Jain M, Bandyopadhyay D, etal.
Melatonin protects against lipid-
induced mitochondrial dysfunction
in hepatocytes and inhibits stellate
cell activation during hepatic fibrosis
in mice. Journal of Pineal Research.
[108] Donato AJ, Morgan RG,
Walker AE, Lesniewski LA.Cellular and
molecular biology of aging endothelial
cells. Journal of Molecular and Cellular
Cardiology. 2015;:122-135
[109] Xu S, Pi H,Zhang L, Zhang N,
Li YM, Zhang H, etal. Melatonin prevents
abnormal mitochondrial dynamics
resulting from the neurotoxicity
of cadmium by blocking calcium-
dependent translocation of Drp1 to
the mitochondria. Journal of Pineal
Research. 2016;:291-302
[110] Paradies G, Paradies V, Ruggiero
FM, Petrosillo G.Mitochondrial
bioenergetics decay in aging:
Beneficial effect of melatonin.
Cellular and Molecular Life Sciences.
[111] Ma Z, Xin Z, Di W, Yan X,
Li X, Reiter RJ, etal. Melatonin and
mitochondrial function during
ischemia/reperfusion injury.
Cellular and Molecular Life Sciences.
[112] Petrosillo G, Di Venosa N,
Pistolese M, Casanova G, Tiravanti E,
Colantuono G, etal. Protective effect
of melatonin against mitochondrial
dysfunction associated with cardiac
ischemia- reperfusion: Role of
cardiolipin. The FASEB Journal.
[113] Petrosillo G,Moro N,Paradies V,
Ruggiero FM, Paradies G. Increased
susceptibility to Ca2+-induced
permeability transition and to
cytochrome c release in rat heart
mitochondria with aging: Effect of
melatonin. Journal of Pineal Research.
[114] Kang JW, Hong JM, Lee SM.
Melatonin enhances mitophagy and
mitochondrial biogenesis in rats with
carbon tetrachloride-induced liver
fibrosis. Journal of Pineal Research.
[115] Pei HF, Hou JN, Wei FP, Xue Q ,
Zhang F, Peng CF, etal. Melatonin
attenuates postmyocardial infarction
injury via increasing Tom70
expression. Journal of Pineal Research.
[116] Fan ACY, Young JC.Function
of cytosolic chaperones in Tom70-
mediated mitochondrial import. Protein
and Peptide Letters. 2011;:122-131
[117] Lochner A,Marais E, Huisamen B.
Melatonin and cardioprotection against
ischaemia/reperfusion injury: What’s
new? A review. Journal of Pineal
Research. 2018;:e12490
[118] Matsushima S, Sadoshima J.The
role of sirtuins in cardiac disease.
The American Journal of Physiology-
Heart and Circulatory Physiology.
[119] D’Onofrio N,Servillo L,
Balestrieri ML.SIRT1 and SIRT6
signaling pathways in cardiovascular
disease protection. Antioxidants &
Redox Signaling. 2018;:711-732
[120] Yu L, Sun Y, Cheng L,
Jin Z, Yang Y, Zhai M, etal. Melatonin
receptor-mediated protection against
myocardial ischemia/reperfusion
injury: Role of SIRT1. Journal of Pineal
Research. 2014;:228-238
[121] Yu L, Liang H, Dong X, Zhao G,
Jin Z, Zhai M, etal. Reduced silent
information regulator 1 signaling
exacerbates myocardial ischemia-
reperfusion injury in type 2 diabetic
rats and the protective effect of
melatonin. Journal of Pineal Research.
[122] Mayo JC, Sainz RM, González
Menéndez P, Cepas V, Tan DX,
Reiter RJ.Melatonin and sirtuins: A
“not-so unexpected” relationship.
Journal of Pineal Research.
[123] Yu L, Gong B, Duan W,
Fan C, Zhang J, Li Z, etal. Melatonin
ameliorates myocardial ischemia/
reperfusion injury in type 1 diabetic rats
by preserving mitochondrial function:
Role of AMPK-PGC-1α-SIRT3 signaling.
Scientific Reports. 2017;:41337
[124] Chua S, Lee F-YY, Chiang H-JJ, Chen
K-HH, Lu H-II, Chen Y-TTY-LL, etal. The
cardioprotective effect of melatonin and
exendin-4 treatment in a rat model of
cardiorenal syndrome. Journal of Pineal
Research. 2016;:438-456
[125] Majidinia M, Sadeghpour A,
Mehrzadi S, Reiter RJ, Khatami N,
Yousefi B.Melatonin: A pleiotropic
molecule that modulates DNA damage
response and repair pathways. Journal
of Pineal Research. 2017;:e12416
[126] Ben SI, Mies F, Naeije R,
Shlyonsky V.Melatonin
Melatonin for a Healthy Heart Rhythm
DOI: hp://
down-regulates volume-sensitive
chloride channels in fibroblasts.
Pflügers Archiv: European Journal of
Physiology. 2012;:273-285
[127] Diez ER, Prados LV, Carrión A,
Ponce ZAZ, Miatello RM.A novel
electrophysiologic effect of
melatonin on ischemia/reperfusion-
induced arrhythmias in isolated rat
hearts. Journal of Pineal Research.
[128] Diez ER, Prado NJ,Carrión AM,
Petrich ER, Ponce Zumino AZ,
Miatello RM.Electrophysiological
effects of tamoxifen: Mechanism
of protection against reperfusion
arrhythmias in isolated rat
hearts. Journal of Cardiovascular
Pharmacology. 2013;:184-191
[129] Varga Z, Panyi G, Péter M,
Pieri C, Csécsei G, Damjanovich S, etal.
Multiple binding sites for melatonin
on Kv1.3. Biophysical Journal.
[130] Hablitz LM,Molzof HE,
Abrahamsson KE, Cooper JM,
Prosser RA, Gamble KL.GIRK channels
mediate the nonphotic effects of
exogenous melatonin. The Journal of
Neuroscience. 2015;:14957-14965
[131] Nelson CS, Marino JL,Allen CN.
Melatonin receptors activate heteromeric
G-protein coupled Kir3 channels.
Neuroreport. 1996;:717-720
[132] Huang Y, Li Y, Leng Z.Melatonin
inhibits GABAergic neurons in the
hypothalamus consistent with a
reduction in wakefulness. Neuroreport.
[133] Waseem M,Tabassum H,
Parvez S.Melatonin modulates
permeability transition pore and
5-hydroxydecanoate induced KATP
channel inhibition in isolated brain
mitochondria. Mitochondrion.
[134] Mohammadi F, Shakiba S,
Mehrzadi S, Afshari K, Rahimnia AH,
Dehpour AR.Anticonvulsant effect
of melatonin through ATP-sensitive
channels in mice. Fundamental &
Clinical Pharmacology. 2020;:148-155
[135] Brown DA, Aon MA, Frasier CR,
Sloan RC, Maloney AH, Anderson EJ,
etal. Cardiac arrhythmias induced
by glutathione oxidation can be
inhibited by preventing mitochondrial
depolarization. Journal of Molecular and
Cellular Cardiology. 2010;:673-679
[136] Nakaya H.Role of ATP-
sensitive K+ channels in cardiac
arrhythmias. Journal of Cardiovascular
Pharmacology and Therapeutics.
[137] Ayar A, Martin DJ, Ozcan M,
Kelestimur H.Melatonin inhibits high
voltage activated calcium currents
in cultured rat dorsal root ganglion
neurones. Neuroscience Letters.
[138] Choi TY, Kwon JE, Durrance ES,
Jo SH, Choi SY, Kim KT.Melatonin
inhibits voltage-sensitive Ca2+ channel-
mediated neurotransmitter release.
Brain Research. 2014;:34-42
[139] Escames G, Macías M, León J,
García J, Khaldy H, Martín M, etal.
Calcium-dependent effects of
melatonin inhibition of glutamatergic
response in rat striatum. Journal of
Neuroendocrinology. 2001;:459-466
[140] Mei YA, Lee PPN, Wei H,
Zhang ZH, Pang SF.Melatonin and
its analogs potentiate the nifedipine-
sensitive high-voltage-activated calcium
current in the chick embryonic heart
cells. Journal of Pineal Research.
[141] Mück AO, Seeger H, Bartsch C,
Lippert TH.Does melatonin affect
calcium influx in human aortic smooth
muscle cells and estradiol-mediated
calcium antagonism? Journal of Pineal
Research. 1996;:145-147
[142] Chen LD, Kumar P, Reiter RJ,
Tan DX, Chamber JP, Manchester LC,
etal. Melatonin reduces 3H-nitrendipine
binding in the heart. Proceedings of the
Society for Experimental Biology and
Medicine. 1994;:34-37
[143] Xu Z, Wu Y, Zhang Y, Zhang H,
Shi L. Melatonin activates BKCa
channels in cerebral artery myocytes
via both direct and MT receptor/PKC-
mediated pathway. European Journal of
Pharmacology. 2019;:177-188
[144] Al Dera H, Alassiri M, Eleawa SM,
AlKhateeb MA, Hussein AM, Dallak M,
etal. Melatonin improves memory
deficits in rats with cerebral
hypoperfusion, possibly, through
decreasing the expression of small-
conductance Ca2+-activated K+
channels. Neurochemical Research.
[145] Ovali MA, Uzun M.The effects
of melatonin administration on
KCNQ and KCNH2 gene expressions
and QTc interval in pinealectomised
rats. Cellular and Molecular Biology.
[146] Arntz HR, Willich SN, Oeff M,
Brüggemann T, Stern R, Heinzmann A,
etal. Circadian variation of sudden
cardiac death reflects age-related
variability in ventricular fibrillation.
Circulation. 1993;:2284-2289
[147] Tribulova N, SzeiffovaBacova B,
Benova T, Viczenczova C.Can we
protect from malignant arrhythmias
by modulation of cardiac cell-to-cell
coupling? Journal of Electrocardiology.
[148] Babiker F,Al-Jarallah A,
Al-Awadi M.Effects of cardiac
hypertrophy, diabetes, aging, and
pregnancy on the Cardioprotective
effects of Postconditioning in male and
female rats. Cardiology Research and
Practice. 2019;:3403959
[149] Carro J, Pueyo E, Rodríguez
Matas JF.A response surface
optimization approach to adjust ionic
current conductances of cardiac
electrophysiological models. Application
to the study of potassium level changes.
PLoS One. 2018;:e0204411
[150] Johnson R, Camelliti P.Role of
non-Myocyte gap junctions
and Connexin Hemichannels in
cardiovascular health and disease:
Novel therapeutic targets? International
Journal of Molecular Sciences.
[151] Pk W, Whelton PK, Carey RM,
Aronow WS, Ovbiagele B, Casey DE,
etal. Guideline for the prevention,
detection, evaluation, and management
of high blood pressure in adults. Journal
of American College of Cardiology.
[152] Steinberg C, Laksman ZWM,
Krahn AD.Sudden cardiac death: A
reappraisal. Trends in Cardiovascular
Medicine. 2016;:709-719
[153] Ibanez B, James S,Agewall S,
Antunes MJ, Bucciarelli-Ducci C,
Bueno H, etal. 2017 ESC guidelines for
the management of acute myocardial
infarction in patients presenting with
ST-segment elevation. European Heart
Journal. 2018;:119-177
[154] Roth GA, Huffman MD,
Moran AE, Feigin V, Mensah GA,
Naghavi M, etal. Global and regional
patterns in cardiovascular mortality
from 1990 to 2013. Circulation.
[155] Ambale-Venkatesh B,Yang X,
Wu CO, Liu K, Hundley WG,
McClelland R, etal. Cardiovascular
event prediction by machine
learning. Circulation Research.
Melatonin for a Healthy Heart Rhythm
DOI: hp://
[156] Adabag AS, Luepker RV,
Roger VL, Gersh BJ.Sudden cardiac
death: Epidemiology and risk
factors. Nature Reviews. Cardiology.
[157] Li Y, Nantsupawat T,
Tholakanahalli V, Adabag S, Wang Z,
Benditt DG, etal. Characteristics and
periodicity of sustained ventricular
tachyarrhythmia events in a population
of military veterans with implantable
cardioverter defibrillator. Journal of
Interventional Cardiac Electrophysiology.
2019. DOI: 10.1007/s10840-019-00569-0.
[Epub ahead of print]
[158] Tang PT, Shenasa M, Boyle NG.
Ventricular arrhythmias and sudden
cardiac death. Cardiac Electrophysiology
Clinics. 2017;:693-708
[159] Tan D-X, Manchester LC, Reiter RJ,
Qi W, Kim SJ, El-Sokkary GH.Ischemia/
reperfusion-induced arrhythmias in
the isolated rat heart: Prevention by
melatonin. Journal of Pineal Research.
[160] Lagneux C, Joyeux M, Demenge P,
Ribuot C, Godin-Ribuot D.Protective
effects of melatonin against ischemia-
reperfusion injury in the isolated rat
heart. Life Sciences. 2000;:503-509
[161] Szárszoi O, Asemu G, Vaněček J,
Ošt’ádal B, Kolář F.Effects of melatonin
on ischemia and reperfusion injury of
the rat heart. Cardiovascular Drugs and
Therapy. 2001;:251-257
[162] Kaneko S, Okumura K,
Numaguchi Y, Matsui H, Murase K,
Mokuno S, etal. Melatonin scavenges
hydroxyl radical and protects isolated
rat hearts from ischemic reperfusion
injury. Life Sciences. 2000;:101-112
[163] Lee YM, Chen HR, Hsiao G,
Sheu JR, Wang JJ, Yen MH.Protective
effects of melatonin on myocardial
ischemia/reperfusion injury
invivo. Journal of Pineal Research.
[164] Bertuglia S, Reiter RJ.Melatonin
reduces ventricular arrhythmias and
preserves capillary perfusion during
ischemia-reperfusion events in
cardiomyopathic hamsters. Journal of
Pineal Research. 2007;:55-63
[165] Važan R, Pancza D, Béder I,
Styk J.Ischemia-reperfusion injury—
Antiarrhythmic effect of melatonin
associated with reduced recovering of
contractility. General Physiology and
Biophysics. 2005;:355-359
[166] Vazan R, Ravingerova T.Protective
effect of melatonin against myocardial
injury induced by epinephrine. Journal
of Physiology and Biochemistry.
[167] Dobsak P, Siegelova J, Eicher JC,
Jancik J, Svacinova H, Vasku J, etal.
Melatonin protects against ischemia-
reperfusion injury and inhibits
apoptosis in isolated working rat heart.
Pathophysiology. 2003;:179-187
[168] Diez ER, Renna NF,Prado NJ,
Lembo C, Ponce Zumino AZ,
Vazquez-Prieto M, etal. Melatonin,
given at the time of reperfusion,
prevents ventricular arrhythmias
in isolated hearts from fructose-fed
rats and spontaneously hypertensive
rats. Journal of Pineal Research.
[169] Benova T, Viczenczova C,
Radosinska J, Bacova B, Knezl V,
Dosenko V, etal. Melatonin attenuates
hypertension-related proarrhythmic
myocardial maladaptation of
connexin-43 and propensity of the heart
to lethal arrhythmias. Canadian Journal
of Physiology and Pharmacology.
[170] Lee S, Kang E, Yoo KD, Choi Y,
Kim DK, Joo KW, etal. Lower serum
potassium associated with increased
mortality in dialysis patients: A
nationwide prospective observational
cohort study in Korea. PLoS One.
[171] Pun PH,Goldstein BA,
Gallis JA, Middleton JP, Svetkey LP.
Serum potassium levels and risk of
sudden cardiac death among patients
with chronic kidney disease and
significant coronary artery disease.
Kidney International Reports.
[172] Osadchii OE.Electrophysiological
determinants of arrhythmic
susceptibility upon endocardial and
epicardial pacing in Guinea-pig heart.
Acta Physiologica. 2012;:494-506
[173] Osadchii OE.Impact of
hypokalemia on electromechanical
window, excitation wavelength and
repolarization gradients in guinea-
pig and rabbit hearts. PLoS One.
[174] Osadchii OE.Effects of
antiarrhythmics and hypokalemia
on the rate adaptation of cardiac
repolarization. Scandinavian
Cardiovascular Journal.
[175] Xie Y, Sato D, Garfinkel A, Qu Z,
Weiss JN.So little source, so much sink:
Requirements for after depolarizations
to propagate in tissue. Biophysical
Journal. 2010;:1408-1415
[176] Osadchii OE.Mechanisms of
hypokalemia-induced ventricular
arrhythmogenicity. Fundamental
& Clinical Pharmacology.
[177] Ek-Vitorín J,Pontifex T,
Burt J, Ek-Vitorín JF, Pontifex TK,
Burt JM.Cx43 channel gating and
permeation: Multiple phosphorylation-
dependent roles of the carboxyl
terminus. International Journal of
Molecular Sciences. 2018;:1659
[178] Palatinus JA,O’Quinn MP,
Barker RJ, Harris BS, Jourdan J,
Gourdie RG.ZO-1 determines adherens
and gap junction localization at
intercalated disks. The American Journal
of Physiology: Heart and Circulatory
Physiology. 2011;:H583-H594
[179] Iyyathurai J, Himpens B,
Bultynck G, D’hondt C.Calcium wave
propagation triggered by local
mechanical stimulation as a method
for studying gap junctions and
hemichannels. Methods in Molecular
Biology (Clifton, NJ). 2016;:203-211
[180] Dhein S, Seidel T, Salameh A,
Jozwiak J, Hagen A, Kostelka M, etal.
Remodeling of cardiac passive electrical
properties and susceptibility to
ventricular and atrial arrhythmias.
Frontiers in Physiology. 2014;:424
[181] Xie Y,Garfinkel A,Camelliti P,
Kohl P, Weiss JN, Qu Z.Effects of
fibroblast-myocyte coupling on cardiac
conduction and vulnerability to reentry:
A computational study. Heart Rhythm.
[182] Remo BF, Qu J, Volpicelli FM,
Giovannone S, Shin D, Lader J, etal.
Phosphatase-resistant gap junctions
inhibit pathological remodeling and
prevent arrhythmias. Circulation
Research. 2011;:1459-1466
[183] Hoppe LK,Muhlack DC,
Koenig W, Carr PR, Brenner H,
Schöttker B.Association of abnormal
serum potassium levels with
arrhythmias and cardiovascular
mortality: A systematic review and
meta-analysis of observational studies.
Cardiovascular Drugs and Therapy.
[184] Trenor B, Cardona K, Romero L,
Gomez JF, Saiz J, Rajamani S, etal. Pro-
arrhythmic effects of low plasma [K+] in
human ventricle: An illustrated review.
Trends in Cardiovascular Medicine.
Melatonin for a Healthy Heart Rhythm
DOI: hp://
[185] Ishigaki S, Ohashi N,Isobe S,
Tsuji N, Iwakura T, Ono M, etal.
Impaired endogenous nighttime
melatonin secretion relates to intrarenal
renin-angiotensin system activation
and renal damage in patients with
chronic kidney disease. Clinical
and Experimental Nephrology.
[186] Zetner D,Andersen L,
Rosenberg J. Pharmacokinetics of
alternative administration routes of
melatonin: A systematic review. Drug
Research (Stuttgart). 2015;:169-173
[187] Andersen LPH, Gögenur I,
Rosenberg J, Reiter RJ.The safety of
melatonin in humans. Clinical Drug
Investigation. 2016;:169-175
[188] Gul-Kahraman K, Yilmaz-
Bozoglan M, Sahna E.Physiological and
pharmacological effects of melatonin on
remote ischemic perconditioning after
myocardial ischemia-reperfusion injury
in rats: Role of Cybb, Fas, NfκB, Irisin
signaling pathway. Journal of Pineal
Research. 2019;:e12589
[189] Sahna E, Olmez E, Acet A.Effects
of physiological and pharmacological
concentrations of melatonin on
ischemia-reperfusion arrhythmias
in rats: Can the incidence of sudden
cardiac death be reduced? Journal of
Pineal Research. 2002;:194-198
[190] Dominguez-Rodriguez A,
Abreu-Gonzalez P, Reiter RJ.Circadian
variation in acute myocardial infarction
size: Likely involvement of the
melatonin and suprachiasmatic nuclei.
International Journal of Cardiology.
[191] Nagibin V, Egan
Benova T, Viczenczova C, Szeiffova
Bacova B, Dovinova I, Barancik M,
etal. Ageing related down-regulation
of myocardial connexin-43 and
up-regulation of MMP-2 may predict
propensity to atrial fibrillation in
experimental animals. Physiological
Research. 2016;(Suppl 1):S91-S100
[192] Sedova KA, Bernikova OG,
Cuprova JI, Ivanova AD, Kutaeva GA,
Pliss MG, etal. Association between
antiarrhythmic, electrophysiological,
and Antioxidative effects of melatonin
in ischemia/reperfusion. International
Journal of Molecular Sciences.
[193] Al-Khatib SM,Stevenson WG,
Ackerman MJ, Bryant WJ,Callans DJ,
Curtis AB, etal. AHA/ACC/HRS
guideline for management of patients
with ventricular arrhythmias and the
prevention of sudden cardiac death:
Executive summary: A report of the
American College of Cardiology/
American Heart Association task force
on clinical practice Gui. Heart Rhythm.
[194] Li J, Hu D, Song X, Han T,
Gao Y, Xing Y.The role of biologically
active ingredients from natural drug
treatments for arrhythmias in different
mechanisms. BioMed Research
International. 2017;:1-10
[195] Al-Gobari M, Al-Aqeel S,
Gueyffier F, Burnand B.Effectiveness
of drug interventions to prevent sudden
cardiac death in patients with heart
failure and reduced ejection fraction:
An overview of systematic reviews. BMJ
Open. 2018;:e021108
[196] Erath JW, Hohnloser SH.Drugs
to prevent sudden cardiac death.
International Journal of Cardiology.
[197] Zanoboni A, Zanoboni-
MuciacciaW. Experimental
hypertension in pinealectomized rats.
Life Sciences. 1967;:2327-2331
[198] Holmes SW, Sugden D.
Proceedings: The effect of melatonin on
pinealectomy-induced hypertension in
the rat. British Journal of Pharmacology.
[199] De Farias TDSM, De Oliveira AC,
Andreotti S, Do Amaral FG, Chimin P,
De Proença ARA, etal. Pinealectomy
interferes with the circadian clock
genes expression in white adipose
tissue. Journal of Pineal Research.
[200] Simko F, Pechanova O.
Remodelling of the heart and vessels in
experimental hypertension: Advances
in protection. Journal of Hypertension.
2010;(Suppl 1):S1-S6
[201] Russcher M, Koch B, NagtegaalE,
van der Putten K, ter Wee P, GaillardC.
The role of melatonin treatment in
chronic kidney disease. Frontiers in
Bioscience (Landmark Ed). 2012;:
[202] Campos LA, Cipolla-Neto J,
Amaral FG, Michelini LC, Bader M,
Baltatu OC.The angiotensin-melatonin
Axis. International Journal of
Hypertension. 2013;:1-7
[203] Ishigaki S,Ohashi N,
Matsuyama T, Isobe S, Tsuji N,
Iwakura T, etal. Melatonin ameliorates
intrarenal renin–angiotensin system
in a 5/6 nephrectomy rat model.
Clinical and Experimental Nephrology.
[204] Franczyk-Skóra B, Gluba-
BrzózkaA, Wranicz JK, BanachM,
Olszewski R, Rysz J.Suddencardiac
death in CKD patients. International
Urology and Nephrology. 2015;:
[205] Pun PH.The interplay between
CKD, sudden cardiac death, and
ventricular arrhythmias. Advances
in Chronic Kidney Disease.
[206] Bonato FOB, Canziani MEF,
Bonato FOB, Canziani MEF.Ventricular
arrhythmia in chronic kidney disease
patients. Jornal Brasileiro de Nefrologia.
[207] Bonato FOB,Watanabe R,
Lemos MM, Cassiolato JL,Wolf M,
Canziani MEF. Asymptomatic
ventricular arrhythmia and clinical
outcomes in chronic kidney disease: A
pilot study. The Journal CardioRenal
Medicine. 2016;:66-73
[208] Reddan DN, Szczech L,
Bhapkar MV, Moliterno DJ, Califf RM,
Ohman EM, etal. Renal function,
concomitant medication use and
outcomes following acute coronary
syndromes. Nephrology, Dialysis,
Transplantation. 2005;:2105-2112
[209] Diez ER,Altamirano LB,
García IM, Mazzei L, Prado NJ,
Fornes MW, etal. Heart remodeling
and ischemia–reperfusion arrhythmias
linked to myocardial vitamin D
receptors deficiency in obstructive
nephropathy are reversed by
Paricalcitol. Journal of Cardiovascular
Pharmacology and Therapeutics.
[210] Mazzei L, Docherty NG,
Manucha W.Mediators and mechanisms
of heat shock protein 70 based
cytoprotection in obstructive
nephropathy. Cell Stress & Chaperones.
[211] Lutz W, Kohno K, Kumar R.The
role of heat shock protein 70in vitamin
D receptor function. Biochemical and
Biophysical Research Communications.
[212] Ferder M,Inserra F,Manucha W,
Ferder L.The world pandemic of
vitamin D deficiency could possibly
be explained by cellular inflammatory
response activity induced by the renin-
angiotensin system. The American
Journal of Physiology-Cell Physiology.
[213] García IM, Altamirano L,
Mazzei L, Fornés M, Cuello-Carrión FD,
Ferder L, etal. Vitamin D receptor-
modulated Hsp70/AT1 expression may
Melatonin for a Healthy Heart Rhythm
DOI: hp://
protect the kidneys of SHRs at the
structural and functional levels. Cell
Stress & Chaperones. 2014;:479-491
[214] McElwee SK, Velasco A,
Doppalapudi H.Mechanisms of sudden
cardiac death. Journal of Nuclear
Cardiology. 2016;:1368-1379
[215] van denTop M,Buijs RM,
Ruijter JM, Delagrange P, Spanswick D,
Hermes ML.Melatonin generates
an outward potassium current in rat
suprachiasmatic nucleus neurones
invitro independent of their circadian
rhythm. Neuroscience. 2001;:99-108
[216] Hou S-W, Zheng P, Sun F-Y.
Melatonin inhibits outward delayed
rectifier potassium currents in
hippocampal CA1 pyramidal neuron
via intracellular indole-related
domains. Journal of Pineal Research.
[217] Yang XF, Miao Y, Ping Y, Wu HJ,
Yang XL, Wang Z.Melatonin inhibits
potassium channels of rod ON type
bipolar cells via MT2 receptors in rat
retina. Neuroscience. 2011;:19-29
Full-text available
Aging comes with gradual loss of functions that increase the vulnerability to disease, senescence, and death. The mechanisms underlying these processes are linked to a prolonged imbalance between damage and repair. Damaging mechanisms include oxidative stress, mitochondrial dysfunction, chronodisruption, inflammation, and telomere attrition, as well as genetic and epigenetic alterations. Several endogenous tissue repairing mechanisms also decrease. These alterations associated with aging affect the entire organism. The most devastating manifestations involve the cardiovascular system and may lead to lethal cardiac arrhythmias. Together with structural remodeling, electrophysiological and intercellular communication alterations during aging predispose to arrhythmic events. Despite the knowledge on repairing mechanisms in the cardiovascular system, effective antiaging strategies able to reduce the risk of arrhythmias are still missing. Melatonin is a promising therapeutic candidate due to its pleiotropic actions. This indoleamine regulates chronobiology and endocrine physiology. Of relevance, melatonin is an antiaging, antioxidant, antiapoptotic, antiarrhythmic, immunomodulatory, and antiproliferative molecule. This review focuses on the protective effects of melatonin on age-induced cardiac functional and structural alterations, potentially becoming a new fountain of youth for the heart.
Full-text available
Melatonin is assumed to confer cardioprotective action via antioxidative properties. We evaluated the association between ventricular tachycardia and/or ventricular fibrillation (VT/VF) incidence, oxidative stress, and myocardial electrophysiological parameters in experimental ischemia/reperfusion under melatonin treatment. Melatonin was given to 28 rats (10 mg/kg/day, orally, for 7 days) and 13 animals received placebo. In the anesthetized animals, coronary occlusion was induced for 5 min followed by reperfusion with recording of unipolar electrograms from ventricular epicardium with a 64-lead array. Effects of melatonin on transmembrane potentials were studied in ventricular preparations of 7 rats in normal and “ischemic” conditions. Melatonin treatment was associated with lower VT/VF incidence at reperfusion, shorter baseline activation times (ATs), and activation-repolarization intervals and more complete recovery of repolarization times (RTs) at reperfusion (less baseline-reperfusion difference, ΔRT) (p < 0.05). Superoxide dismutase (SOD) activity was higher in the treated animals and associated with ΔRT (p = 0.001), whereas VT/VF incidence was associated with baseline ATs (p = 0.020). In vitro, melatonin led to a more complete restoration of action potential durations and resting membrane potentials at reoxygenation (p < 0.05). Thus, the antioxidative properties of melatonin were associated with its influence on repolarization duration, whereas the melatonin-related antiarrhythmic effect was associated with its oxidative stress-independent action on ventricular activation.
Full-text available
Cardiovascular and neurological diseases can originate in early life. Melatonin, a biologically active substance, acts as a pleiotropic hormone essential for pregnancy and fetal development. Maternal melatonin can easily pass the placenta and provide photoperiodic signals to the fetus. Though melatonin uses in pregnant or lactating women have not yet been recommended, there is a growing body of evidence from animal studies in support of melatonin as a reprogramming strategy to prevent the developmental programming of cardiovascular and neurological diseases. Here, we review several key themes in melatonin use in pregnancy and lactation within offspring health and disease. We have particularly focused on the following areas: the pathophysiological roles of melatonin in pregnancy, lactation, and fetal development; clinical uses of melatonin in fetal and neonatal diseases; experimental evidence supporting melatonin as a reprogramming therapy to prevent cardiovascular and neurological diseases; and reprogramming mechanisms of melatonin within developmental programming. The targeting of melatonin uses in pregnancy and lactation will be valuable in the prevention of various adult chronic diseases in later life, and especially cardiovascular and neurological diseases.
Full-text available
Human mesenchymal stem cells (hMSCs) are a potent source of cell-based regenerative therapeutics used to treat patients with ischemic disease. However, disease-induced oxidative stress disrupts mitochondrial homeostasis in transplanted hMSCs, resulting in hMSC apoptosis and reducing their efficacy post-transplantation. To address this issue, we evaluated the effects of melatonin on cellular defense mechanisms and mitophagy in hMSCs subjected to oxidative stress. H2O2-induced oxidative stress increases the levels of reactive oxygen species and reduces membrane potential in hMSCs, leading to mitochondrial dysfunction and cell death. Oxidative stress also decreases the expression of 70-kDa heat shock protein 1L (HSPA1L), a molecular chaperone that assists in the recruitment of parkin to the autophagosomal mitochondrial membrane. Decreased expression of HSPA1L destabilizes parkin, thereby impairing mitophagy. Our results indicate that treating hMSCs with melatonin significantly inhibited mitochondrial dysfunction induced by oxidative stress, which decreased hMSCs apoptosis. In damaged hMSCs, treatment with melatonin increased the levels of HSPA1L, which bound to parkin. The interaction between HSPA1L and parkin increased membrane potential and levels of oxidative phosphorylation, resulting in enhanced mitophagy. Our results indicate that melatonin increased the expression of HSPA1L, thereby upregulating mitophagy and prolonging cell survival under conditions of oxidative stress. In this study, we have shown that melatonin, a readily available compound, can be used to improve hMSC-based therapies for patients with pathologic conditions involving oxidative stress.
Full-text available
Free access to the article by reference The purpose of the work on normotensive rats of different age groups (3, 15, and 22 months) is to study the synchronism between the functioning of the cardiovascular system and the locomotor activity of animals in open field tests by a single injection of exogenous melatonin in different doses (1 and 10 mg/kg). The studies show a unidirectional dose-dependent effect of exogenous melatonin on the locomotor activity of rats of different ages and an age-dependent effect of melatonin on the parameters of the cardiovascular system. The results show the possible desynchronization between the circadian rhythms of locomotor activity and the functioning of the cardiovascular system with aging, which can lead to a discrepancy between hemodynamic parameters and the level of locomotor activity.
Full-text available
In this review we summarized the actual clinical data for a cardioprotective therapeutic role of melatonin, listed melatonin and its agonists in different stages of development, and evaluated the melatonin cardiovascular target tractability and prediction using machine learning on ChEMBL. To date, most clinical trials investigating a cardioprotective therapeutic role of melatonin are in phase 2a. Selective melatonin receptor agonists Tasimelteon, Ramelteon, and combined melatonergic-serotonin Agomelatine, and other agonists with registered structures in CHEMBL were not yet investigated as cardioprotective or cardiovascular drugs. As drug-able for these therapeutic targets, melatonin receptor agonists have the benefit over melatonin of well-characterized pharmacologic profiles and extensive safety data. Recent reports of the X-ray crystal structures of MT1 and MT2 receptors shall lead to the development of highly selective melatonin receptor agonists. Predictive models using machine learning could help to identify cardiovascular targets for melatonin. Selecting ChEMBL scores > 4.5 in cardiovascular assays, and melatonin scores > 4, we obtained 284 records from 162 cardiovascular assays carried out with 80 molecules with predicted or measured melatonin activity. Melatonin activities (agonistic or antagonistic) found in these experimental cardiovascular assays and models include arrhythmias, coronary and large vessel contractility, and hypertension. Preclinical proof-of-concept and early clinical studies (phase 2a) suggest a cardioprotective benefit from melatonin in various heart diseases. However, larger phase 3 randomized interventional studies are necessary to establish melatonin and its agonists’ actions as cardioprotective therapeutic agents.
Full-text available
Hypokalemia prolongs the QRS and QT intervals, deteriorates intercellular coupling, and increases the risk for arrhythmia. Melatonin preserves gap junctions and shortens action potential as potential antiarrhythmic mechanisms, but its properties under hypokalemia remain unknown. We hypothesized that melatonin protects against low potassium‐induced arrhythmias through the activation of its receptors, resulting in action potential shortening and connexin‐43 preservation. After stabilization in Krebs‐Henseleit solution (4.5 mEq/L K+), isolated hearts from Wistar rats underwent perfusion with low‐potassium (1 mEq/L) solution and melatonin (100 μM), a melatonin receptor blocker (luzindole, 5 μM), melatonin+luzindole or vehicle. The primary endpoint of the study was the prevention of ventricular fibrillation. Electrocardiography was used, and epicardial action potentials and heart function were measured and analyzed. The ventricular expression, dephosphorylation, and distribution of connexin‐43 were examined. Melatonin reduced the incidence of low potassium‐induced ventricular fibrillation from 100% to 59%, delayed the occurrence of ventricular fibrillation and induced a faster recovery of sinus rhythm during potassium restitution. Melatonin prevented QRS widening, action potential activation delay, and the prolongation of action potential duration at 50% of repolarization. Other ECG and action potential parameters, the left ventricular developed pressure, and nonsustained ventricular arrhythmias did not differ among groups. Melatonin prevented connexin‐43 dephosphorylation and its abnormal topology (lateralization). Luzindole abrogated the protective effects of melatonin on electrophysiological properties and connexin 43 misdistribution. Our results indicate that melatonin receptor activation protects against low potassium‐induced ventricular fibrillation, shortens action potential duration, preserves ventricular electrical activation, and prevents acute changes in connexin‐43 distribution. All of these properties make melatonin a remarkable antifibrillatory agent. This article is protected by copyright. All rights reserved.
Essentially all biological processes fluctuate over the course of the day, observed at cellular (eg, transcription, translation, and signaling), organ (eg, contractility and metabolism), and whole-body (eg, physical activity and appetite) levels. It is, therefore, not surprising that both cardiovascular physiology (eg, heart rate and blood pressure) and pathophysiology (eg, onset of adverse cardiovascular events) oscillate during the 24-hour day. Chronobiological influence over biological processes involves a complex interaction of factors that are extrinsic (eg, neurohumoral factors) and intrinsic (eg, circadian clocks) to cells. Here, we focus on circadian governance of 6 fundamentally important processes: metabolism, signaling, electrophysiology, extracellular matrix, clotting, and inflammation. In each case, we discuss (1) the physiological significance for circadian regulation of these processes (ie, the good); (2) the pathological consequence of circadian governance impairment (ie, the bad); and (3) whether persistence/augmentation of circadian influences contribute to pathogenesis during distinct disease states (ie, the ugly). Finally, the translational impact of chronobiology on cardiovascular disease is highlighted.
Although melatonin is necessary for circadian regulation of sleep, the mechanisms underlying this effect of melatonin are still unclear. In the present study, we showed that melatonin suppressed the activity of GABAergic neurons in the lateral hypothalamus, which has been reported to play a crucial role in maintaining wakefulness. The inhibitory effect of the melatonin was mediated by activation of melatonin 1 receptors and depended on the inhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels. At behavioral levels, infusion of melatonin into the lateral hypothalamus significantly decreased the locomotor and exploratory activities and increased the time of immobility in open filed. Additionally, using electroencephalogram (EEG) and electromyogram (EMG) recordings, we found that infusion of melatonin into the lateral hypothalamus decreased the time spent in wakefulness and increased the amount of sleep. Overall, these results suggest that melatonin inhibits GABAergic neurons in the lateral hypothalamus via melatonin 1 receptor-dependent inhibition of the HCN channels, which is consistent with a decrease in wakefulness. These findings provide a new mechanism underlying the hypnotic effect of the melatonin.
Oxidative stress is a result of imbalance between cellular oxidants and antioxidants. The oxidants like Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are considered to induce many pathological processes including heart failure. They target the ion channels for any kind of modifications or mutations that alter the channels' usual function. There are evidences showing oxidative stress to modulate the ion channels and transporters that play crucial role in general physiology of heart, leading to many prevalent cardiovascular disorders including atrial fibrillation (AF). Though the fundamental cause of AF is not still understood, but modulation of Kv1.5 channel has been successfully proved to be one of the strategic therapeutic interventions. In this chapter, the current knowledge on the effects of oxidative stress in heart has been summarized along with the roles of ion channels and their modulation.
Previous studies confirmed that melatonin regulates Runx2 expression but the mechanism is unclear. There is a direct interaction between Runx2 and the vitamin D receptor (VDR). Herein, we observed a direct interaction between melatonin and the VDR but not Runx2 using isothermal titration calorimetry. Furthermore, this direct binding was detected only in the C‐terminal ligand binding domain (LBD) of the VDR but not in the N‐terminal DNA binding domain (DBD) or the hinge region. Spectrophotometry indicated that melatonin and vitamin D3 (VD3) had similar uptake rates, but melatonin's uptake was significantly inhibited by VD3 until the concentration of melatonin was obviously higher than that of VD3 in a preosteoblastic cell line MC3T3‐E1. GST pull down and yeast two‐hybrid assay showed that the interactive smallest fragments were on the 319‐379 position of Runx2 and the N‐terminus 110‐amino acid DBD of the VDR. Electrophoretic mobility shift assay (EMSA) demonstrated that Runx2 facilitated the affinity between the VDR and its specific DNA substrate, which was further documented by a fluorescent EMSA assay where Cy3 labeled Runx2 co‐localized with the VDR‐DNA complex. Another fluorescent EMSA assay confirmed that the binding of the VDR to Runx2 was significantly enhanced with an increasing concentrations of the VDR, especially in the presence of melatonin; it was further documented using a co‐immunoprecipitation assay that this direct interaction was markedly enhanced by melatonin treatment in the MC3T3‐E1 cells. Thus, the VDR is a novel melatonin‐binding nuclear receptor, and melatonin indirectly regulates Runx2 when it directly binds to the LBD and the DBD of the VDR, respectively.